De osteoporotische femurkop bij de oudere: het probleem van fractuurfixatie en preventie by Sermon, An
 
  
 
 
KU Leuven 
Biomedical Sciences Group 
Faculty of Medicine 
Department of Development and Regeneration 
 
 
 
 
 
 
 
 
Addressing the challenge of  
hip fracture fixation and  
prevention in old age  
 
Preclinical and clinical studies  
assessing the osteoporotic  
femoral head  
 
An Sermon 
 
 
 
 
Leuven, November 2014 
II 
  
 
 
Promoter:  Prof. Dr. J. Flamaing 
Co-promoter:  Prof. Dr. S. Boonen
†
 
   Prof. Dr. P. Broos 
   Prof. R. Richards 
Chair:   Prof. Dr. P. Debeer 
Secretary:   Prof. F. Staes 
Jury members:   Prof. Dr. M. Fransen 
   Prof. Dr. C. Kammerlander 
   Prof. Dr. T. Scheerlinck 
   Prof. Dr. JP. Simon 
    
 
Cover picture courtesy of the AO Foundation 
 
 
 
 
 
 
Dissertation presented in partial 
fulfillment of the requirements for  
the degree of Doctor in Biomedical 
Sciences 
 
III 
  
 
 
 
 
 
 
 
 
 
 
 
 
  To Steven Boonen  
 
 
IV 
  
Bedankt  
De mooiste les geleerd uit dit onderzoeksproject is de samenwerking die ik heb 
kunnen uitbouwen met tal van mensen, van wie velen me zeer dierbaar zijn 
geworden. Mijn oprechte dank gaat dan ook uit naar allen hieronder vermeld: 
zonder jullie was deze thesis niet mogelijk geweest! 
 
 
 
  Mariette      Peggy         Carine   
 Administratieve ondersteuning 
 Eline       Kathleen         Meri    Vera  
    
  
               Barbara      Ilse       Matthias 
          Studenten 
                Michiel   Thirsa    Bastiaan 
     Prof. M. Decramer 
  Fellows    Assistenten OK 
 Co-assistenten   Hoofdverpleegkundigen 
    Prof. P. De Leyn   Stefaan Paul   
     UZLeuven     Collega's 
 Prof. J. Van Eldere            Ergo       Dominique Harm 
  Kine  Verpleegeenheden 
       Sociale dienst 
  Dienst Geriatrie    Centrum voor Metabole 
         Botziekten 
 
   Prof. R. Torfs 
Prof. J. Goffin Prof. W. Robberecht    Doctoral school  Biostat 
   KULeuven           S. Fieuws 
 Prof. J. Deprest          
     
        Prof. P. Debeer   
  Prof. M. Fransen  Prof. F. Staes 
    TAC   
      Prof. JP. Simon  Prof. T. Scheerlinck  
         JURY 
        Prof. C. Kammerlander   
    Prof. J. Flamaing    Prof. S. Boonen 
        Prof. P. Broos 
      Thesis begeleiders 
        Prof. G. Richards 
 
V 
  
Thank you 
The most beautiful lesson of this research project is the collaboration I could 
develop with a lot of people. Some of them became very precious to me. My sincere 
thanks go to all of the following people: without you the writing of this thesis would 
not have been possible! 
 
 
   Markus 
  Lukas Sonia 
              Erich  Jan  Benno     
  Damiano Geoff     
   ARI      
           Dieter  Ladina Boyko     
              Ronny Karsten Vincent 
  Yash  Ivan  Dirk  Deso    Prof. S. Kates 
       Prof. M. Blauth Prof. P. Reynders 
        Colleagues 
        Prof. M. Hanssens 
 
  AZ Groeninge Kortrijk       
             AZ Sint-Maria Halle  UZ Gasthuisberg Leuven  
  Opleiders           
                     AZ Sint-Blasius Dendermonde 
 
           Lieven  
             De Puy - Synthes 
                 Jo          Andre 
  Koen Milisen  Deborah Seys 
 Affiliated research lines 
 Ilke Montag   Kris Vanhaecht 
 
 
    Jan en Marieke & kids  
        Moeke en vake 
       Familie     Luc 
     Meter   Lucas 
       3S 
      
        The audience 
  YOU 
          The reader     Patiënten 
 
 
VI 
  
VII 
  
Table of contents  
 
General introduction 1 
 1.  Definition and diagnosis of osteoporosis 3 
 2.  Consequences of osteoporotic hip fractures for the individual patient 4 
 3.  Economic consequences of fragility hip fractures 5 
 4.  The role of co-managed care and clinical pathways in fragility hip 
fracture treatment  6 
 5.  Secondary fracture prevention  6 
 6.  Influence of osteoporosis on the surgical treatment of fragility hip 
fractures and the possible role of augmentation 7 
 7.  References 11 
  
Objectives of the research 17 
 
Chapter I: The impact of care pathways for fragility hip fracture treatment 
 on one-year mortality: systematic literature review and meta- 
 analysis  21 
1. Abstract 23 
2. Introduction 24 
3. Materials and methods 26 
 3.1. Data sources and searches 26 
 3.2. Inclusion and exclusion criteria 26 
 3.3. Study selection 27 
 3.4. Methodological quality assessment 27 
 3.5. Care pathway evaluation 28 
 3.6. Data extraction and statistical analysis 28 
 4. Results 29 
 4.1. Study selection 29 
 4.2. Descriptive information 31 
 4.3. Mortality 33 
 4.4. Osteoporosis treatment 33 
 4.5. Recurrent fractures 33 
VIII 
  
 5. Discussion 38 
 5.1. Methodological considerations 38 
  5.2. Considerations on the structure and the content of the clinical 
pathways of the included studies 39 
 5.3. Considerations on the effects of clinical pathways 40 
 5.4. Limitations of the actual study and considerations for further 
research 41 
 6. Conclusion 41 
 7. References 42 
 
Chapter II: The impact of a traumatologic-geriatric post-fracture program 
 for osteoporotic hip fracture patients 45 
1. Abstract 47 
 2. Introduction 48 
 3. Material and methods 50 
3.1. Introduction and implementation of clinical pathway 50 
3.2. Evaluation of clinical pathway 52 
3.3. Statistical analysis 52 
 4. Results 53 
4.1. Clinical pathway implementation 53 
  4.2. Evaluation 54 
   a. General characteristics of the included patients 54 
   b. Process parameters 56 
   c. Outcome parameters 58 
 5. Discussion 62 
  5.1. Development, characteristics and added value of the clinical     
   pathway 62 
  5.2. Comparability of study groups 63 
  5.3. Process parameters 63 
  5.4. Outcome parameters 64 
  5.5. Limitations of the study and outlook 66 
 6. Conclusion 67 
 7. References 68 
IX 
  
Chapter III: Biomechanical evaluation of bone-cement augmented 
 proximal femoral nail antirotation blades in a polyurethane 
 foam model with low density 71 
1. Abstract   73 
 2. Introduction 74 
 3. Materials and methods 76 
  3.1. Specimens and instrumentation 76 
  3.2. Mechanical testing 79 
  3.3. Data acquisition and evaluation 82 
 4. Results  84 
 5. Discussion 88 
 6. Conclusion 91 
 7. Conflict of interest statement 91 
 8. References 92 
 
Chapter IV: Potential of PMMA cement-augmented helical PFNA blades to 
 improve implant stability - a biomechanical investigation in 
 human cadaveric femoral heads 97 
 1. Abstract  99 
 2. Introduction 100 
 3. Materials and methods 101 
 4. Results  106 
 5. Discussion 110 
 6. Conclusion 114 
 7. Acknowledgment 114 
 8. References 115 
 
X 
  
Chapter V: Cement augmentation of hip implants in osteoporotic bone: 
   how much cement is needed and where should it go? 119 
 1. Abstract  121 
 2. Introduction  122 
 3. Methods  123 
  3.1. Study-groups 123 
  3.2. Instrumentation 127 
  3.3. Mechanical testing 130 
  3.4. Data acquisition and evaluation 132 
  3.5. Statistics 132 
 4. Results  133 
 5. Discussion 135 
 6. Conclusion 138 
 7. Conflict of interest statement 138 
 8. Acknowledgments 138 
 9. References 139 
 
General discussion and perspectives 143 
1. Hip fracture prevention 145 
2. Hip fracture fixation 148 
3. Conclusion 155 
4. References 156 
 
Summary 161 
 
Samenvatting 167 
 
Curriculum vitae 173 
 
Scientific publications 177 
XI 
  
List of abbreviations 
3D three dimensional 
AB aktiebolog (Swedish; private limited liability company) 
AG Aktiengesellschaft (German; private limited liability company) 
ANOVA analysis of variance 
AO Arbeitsgemeinschaft für Osteosynthesefragen 
ARI AO research institute 
ASA American society of anaesthesiologists 
ASTM American society for testing and materials 
BMD bone mineral density 
CCD caput collum diaphyseal angle 
CI confidence interval 
CINAHL cumulative index to nursing and allied health literature 
cm centimeter 
CMBD center for metabolic bone diseases 
CT computed tomography 
DEXA  dual energy X-ray absorptiometry 
DHS dynamic hip screw 
e.g. exempli gratia 
et al. et alii 
F force 
FWO fonds wetenschappelijk onderzoek 
FUTime follow-up time  
Ga gauge 
GEMU geriatric assessment and management unit 
GmbH Gesellschaft mit beschränkter Haftung 
H height 
HA hydroxyapatite 
Hz hertz 
i.e. id est 
Inc. incorporated 
IU international unit 
kN kilo newton 
XII 
  
K-wire Kirschner-wire 
L length 
MCU multi-camera control unit 
MeSH medical subject heading 
ml milliliter 
mm millimeter 
MTS mechanical testing system 
MTS corp mechanical testing systems corporation 
N newton 
NRS non-randomized study 
OR odds ratio 
pcf pounds per cubic foot 
PFN proximal femoral nail 
PFNA proximal femoral nail antirotation 
PMMA polymethylmethacrylate 
pQCT  peripheral quantitative computed tomography 
RCT randomized controlled trial 
SD standard deviation 
W width 
TM trade mark 
 
 
 
 
 
 
 
 
 1 
  
 
General introduction 
 
 
 
 2 
  
General introduction 
3 
  
1. Definition and diagnosis of osteoporosis 
Following the internationally agreed definition, osteoporosis is "a systemic skeletal 
disease characterised by low bone mass and microarchitectural deterioration of bone 
tissue".1 These structural changes in cortical and trabecular bone are clearly visible 
on the micro-CT (Computed Tomography) images of a normal (figure 1a) and an 
osteoporotic femoral head (figure 1b) (Images courtesy by Andrea Tami, AO 
(Arbeitsgemeinschaft für Osteosynthesefragen) Research Institute, Davos, 
Switzerland). These transverse slides through the femoral head show the larger 
trabeculae with thinner walls as well as the presence of more empty spaces in the 
osteoporotic specimen. 
 
   
  Figure 1a      Figure 1b 
 
When determining the corresponding bone mineral density by pQCT (peripheral 
Quantitative Computed Tomography), a measurement of volumetric bone mineral 
density is performed, resulting in a lower total, trabecular and cortical density for the 
osteoporotic specimen. In a clinical setting, bone quality measurement is performed 
by DEXA (Dual Energy X-Ray Absorptiometry)-scan. The alterations in osteoporotic 
bone morphology and subsequently bone density1, lead to a higher risk for 
osteoporotic or fragility fractures. Of all fragility fractures, hip fractures constitute the 
most dramatic complication and are a major public health concern. Figure 2 displays 
the X-Ray image of a subtrochanteric fracture in a 95 years old lady. Take notice of 
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the low visibility of the bone with the same density as the calcifications in the femoral 
arteries. 
 
 
          
              Figure 2 
 
2. Consequences of osteoporotic hip fractures for the individual 
patient 
From a clinical perspective, the main consequences of fragility hip fractures are the 
associated morbidity, loss of quality of life, and mortality.2,3 Up to 20-25% of fragility-
related hip fracture patients die within the year following their fracture. Of those who 
do survive, up to 40% will not be able to return to their pre-fracture level of activities 
of daily living with institutionalisation for about 20% of patients because of the 
fracture and its functional consequences.4 Moreover, recent studies show that the 
excess mortality after hip fractures persists over time, for both women and men.5,6 
Furthermore, it has been shown that there is an increased risk of sustaining a 
secondary osteoporotic fracture after a first vertebral, hip or shoulder fracture with the 
highest risk of secondary fractures occurring immediately after the first fracture.7 The 
absolute and relative fracture risk following an initial fragility fracture is the highest in 
case of a preceding hip fracture.8 For women, there is an absolute risk for a 
secondary fracture following a hip fracture of 89 (66-119) per 1000 person-years and 
a relative risk of 2.79 (2.06 – 3.77).8 This finding might be explained by the loss of 
BMD (Bone Mineral Density) that occurs shortly after having sustained a hip fracture. 
General introduction 
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This loss of BMD might continue in the year following the fracture.9 It was also shown 
that the only predictor of decrease in BMD after sustaining a fragility fracture is BMD 
at baseline.10 Interestingly, more than 80% of hip fracture patients have previously 
undiagnosed secondary causes of bone loss of which vitamin D insufficiency, chronic 
kidney disease and calcium malabsorption are the most common.11 
Besides the increased morbidity associated with secondary fractures, subsequent 
fractures also have a highly significant influence on mortality.12 In a prospective 
cohort study on long term mortality following osteoporotic fractures, subsequent 
fracture was associated with an increased mortality hazard ratio of 1.91 (95% CI, 
1.54 – 2.37) in women and 2.99 (95% CI, 2.11 – 4.24) in men. The fracture was only 
in 10.5% mentioned in death certificates as being directly related to the death of the 
patient. The major causes of death were cardiac (27%) and respiratory (26%) 
failure.13 Finally, secondary hip fractures often are complex fractures and are more 
difficult to treat from a surgical point of view. 
The impact of secondary fractures on the individual patient is high. Therefore fragility 
hip fracture treatment should not only focus on the treatment of the actual fracture, 
but also on the treatment of the underlying osteoporosis to reduce the refracture 
risk.8 
 
3. Economic consequences of fragility hip fractures 
During the last decades, a tremendous increase in the number of osteoporosis 
related hip fractures has been noticed due to the active aging of our population. This 
evolution will continue exponentially: in 2025, there will be an estimated three million 
annual incident hip fractures in the United States, creating direct medical costs of       
$ 25 billion.14 These American numbers correspond to similar numbers of fragility hip 
fractures and related costs in Europe: in 2010 there was an incidence of 3.5 million 
osteoporotic fractures generating an economic burden of € 37 billion; these costs will 
increase by 25% in 2025.15 It was calculated in a prospective cohort study with 
matched pair analysis that the costs of treating a hip fracture patient in Belgium are 
three times higher than those of caring for a patient without a fracture.16  
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4. The role of co-managed care and clinical pathways in fragility hip 
fracture treatment 
During the last years, a lot of studies have been published supporting the role of co-
managed care for fragility hip fracture patients.12 It has become clear that an 
orthogeriatric collaboration, passing beyond just good fracture care, will lead to a 
better outcome especially for the very old patients suffering from multiple 
comorbidities.17 Different models of co-managed care have been described, all based 
on a collaboration of surgeons and geriatricians, both more consultative as well as 
integrated care approaches.18 
Furthermore it is clear that care pathways (also known as clinical pathways or critical 
pathways) play a beneficial role in general health care management and more 
specifically in the organization of the care for osteoporotic hip fracture patients.19,20 
As most of the orthogeriatric care models are based on multidisciplinary team work, 
aim at the integration of a package of evidence based key interventions and include 
an active follow-up, they correspond to the definition of care pathways.21 
However, co-managed care and clinical pathways for fragility hip fracture patients as 
well, only focus on short term effects like length of stay and in-hospital or 30-days 
mortality.12,22 Little information is available about long term mortality (at least 1 year 
postoperatively) and about fracture recurrence rates in the years following the first 
fracture. 
 
5. Secondary fracture prevention  
Despite existing guidelines and effective therapies, there is a lack of awareness of 
the incidence and potentially adverse outcomes of senile osteoporosis. The above-
described unfavourable prognosis of osteoporotic hip fractures emphasizes the need 
for secondary fracture prevention. Both pharmacological as non-pharmacological 
interventions (e.g. falls prevention) can reduce the risk of recurrent fractures.23 
With advancing age, calcium intake diminishes as well as the absorptive capacities of 
the body.24 Due to insufficient sunlight exposure and decreased capacity of the skin 
to produce active vitamin D, vitamin D deficiency becomes more prevalent with age 
leading to secondary hyperparathyroidism and bone resorption.25  On the one hand, 
calcium and vitamin D supplementation can reduce the fracture risk in osteoporotic 
patients and is relatively cheap.26 On the other hand, other anti-osteoporotic 
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therapies require optimal calcium and vitamin D levels23 and necessitate adequate 
supplementation. 
From large scale studies, it is clear that antiresorptive (e.g. bisphosphonates) and / or 
anabolic therapies (strontiumranelate, teriparatide) reduce the fracture risk in 
postmenopausal women with osteoporosis27 and reduce the fracture risk and risk of 
death as well in previous hip fracture patients.28 
However, long term compliance to drug therapy is low, especially in patients without 
preceding fracture29 and with advancing age.23 
Only a few research initiatives focus on the possible role of the surgeon treating 
fragility fractures in the post-operative management of the underlying osteoporosis, 
although the first results are promising.30, 31 It is clear that the presence of treatment 
algorithms can be extremely useful.31,32 
 
6. Influence of osteoporosis on the surgical treatment of fragility 
hip fractures and the possible role of augmentation 
In the surgical treatment of osteoporotic hip fractures, two major types of treatment 
can be distinguished based on the fracture type: displaced intracapsular fractures are 
mostly treated by prosthetic replacement and undisplaced intracapsular fractures as 
well as all types of extracapsular fractures are treated by osteosynthesis.33-35  
During the last decades, an evolution in the use of the type of implants for the 
treatment of extracapsular or intertrochanteric fractures has been noticed. Figure 3 
illustrates the two main types of implants that are most frequently used. Figure 3a 
shows an intertrochanteric fracture treated with an extramedullary implant: the 
Dynamic Hip Screw (DHS). Figure 3b shows an intertrochanteric fracture treated with 
an intramedullary implant: the Proximal Femoral Nail Antirotation (PFNA).  
Although there is no evidence that the use of intramedullary implants for the 
treatment of intertrochanteric hip fractures leads to a better outcome35, there is a 
trend towards the use of nails.36 A Cochrane review on the comparison of sliding hip 
screws versus intramedullary implants for the treatment of intertrochanteric fractures 
also suggests further research on new designs of intramedullary nails aimed to 
reduce perioperative fractures.35  
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       Figure 3a                        Figure 3b 
 
Besides the biomechanical advantages of nailing for the treatment of hip fractures37, 
other advantages are: the possibility to use minimal invasive techniques with only 
limited soft tissue damage, a rapid recovery and immediate full weight bearing.38 
Within the intramedullary nailing group, there is no evidence that one type of nail is 
superior to another.39 Several biomechanical studies however support the use of 
nails with blades over nails with standard cephalic screws.40,41 Figure 3b is an 
illustration of a nail with a helical blade to fix the proximal fracture fragment. Despite 
the fact that more and more clinical studies support this finding as well42-44, failures 
do still occur. Cut-out, a devastating complication of perforation of the femoral head 
by the cephalic screw or blade and secondary varisation of the femoral head, can be 
surgeon or bone related. In the first case, an incomplete fracture reduction of an 
unstable fracture or a suboptimal implant positioning can be noticed.42,45,46 If this is 
not the case, it was found that cut-out is strongly related to the density of the 
trabecular bone in the femoral head.47,48 Although the fracture healing potential of 
osteoporotic bone is normal, nonunions or malunions might occur due to implant 
loosening prior to the completion of the fracture healing process.49 The problem of 
implant loosening before fracture healing in a well-reduced fracture, is illustrated in 
figure 4. Figure 4a shows an unstable intertrochanteric fracture in a 80 years old 
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lady. Figure 4b shows the postoperative radiograph: the fracture has been treated 
with an intramedullary nail after closed reduction on a fracture table. Figure 4c and 
4d respectively show the anteroposterior and lateral views of the fracture one month 
postoperatively as a cut-out has occurred: migration of the cephalic screw through 
the femoral head followed by secondary varisation of the proximal fracture fragment.  
 
         
  Figure 4a           Figure 4b 
 
         
  Figure 4c           Figure 4d 
 
Due to the frail constitution of most of the osteoporotic hip fracture patients and due 
to the devastating consequences of revision surgery for these patients, it is of utmost 
importance to prevent mechanical complications and to go for a "one shot surgery". 
In the past, augmentation of hip implants with bone cement has been used to prevent 
these kinds of problems. Cement augmentation has been very useful by increasing 
the strength of the implant fixation, by rapid restoration of the patient’s mobility and 
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by fewer complications due to implant failures.49 The principle of implant 
augmentation is based on increasing the implant to bone interface by the addition of 
bone cement, reducing the stresses on the trabecular structures. 
Polymethylmethacrylate (PMMA) augmentation has been used as a solution to treat 
unstable trochanteric fractures by adding an anchoring ability to the lag screw, 
especially in osteoporotic bone.50 This concept has been proven in numerous 
biomechanical and clinical studies.51-54  
However, a lot of disadvantages have been attributed to cement augmentation. Most 
of them are related to the use of excessive amounts of PMMA. Primarily, impaired 
fracture healing has been mentioned as a consequence of cement leakage at the 
fracture site. This might lead to delayed or non-unions.49,55-58 Secondly, there have 
been some concerns about thermal necrosis of the trabecular bone and the overlying 
cartilage of the femoral head caused by the exothermic reaction of the PMMA 
polymerisation.49,56 Finally, there have been some concerns about implant removal in 
case of revision surgery which might be difficult due to the PMMA present in the 
femoral head.  As absorbable cements are non-toxic and are replaced by host-bone 
over time, their use can overcome the above-described disadvantages related to the 
use of PMMA. Several authors report the successful use of degradable calcium 
phosphate cements in the treatment of intertrochanteric hip fractures in experimental 
and in clinical settings as well.59-61 Nevertheless, the mechanical properties of 
absorbable cements are inferior compared to PMMA62 and their use in osteoporotic 
bone should be questioned as they should be replaced by host bone over time. 
 
In summary, the following two important problems actually are associated to fragility 
hip fracture treatment: the occurrence of secondary fractures and the mechanical 
failure of fixation due to the underlying osteoporotic bone. It is the aim of the current 
research project to focus on both of these problems resulting from important gaps in 
our current knowledge on the prevention and the treatment of fragility hip fractures 
and this from a surgical point of view. 
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The aim of the current doctoral research program is to address the following priorities 
resulting from important gaps in our current knowledge on the prevention and the 
treatment of fragility hip fractures: 
First of all, there is the clinical requirement to implement integrated referral pathways 
that will improve secondary fracture prevention. While it is clear that surgeons play a 
pivotal role in managing fracture patients, few research initiatives attempted to 
optimize post-fracture osteoporosis management by a surgeon-driven team. 
Our second objective will be to investigate the benefits of new implant designs and 
fixation methods in preventing implant failure in osteoporotic bone. This will be done 
by a number of biomechanical experiments. 
According to these priorities, a dual hypothesis will be addressed: 
1) Systematic secondary fracture prevention in the context of a traumatologic-
geriatric fracture prevention program will improve clinical outcome by reducing the 
fracture recurrence rate. 
2) Optimizing existing osteosynthesis methods to fix proximal osteoporotic femoral 
fractures will reduce the complication rate by improving the implant fixation in the 
femoral head. 
In line with both hypotheses, the objectives of the research project can be classified 
along two major research arms: 
1) The development and testing of an integrated secondary fracture prevention 
program. This includes a meta-analysis of the long-term effects of clinical 
pathways for older hip fracture patients (Chapter I) and the development, the 
implementation and the evaluation of a traumatologic-geriatric fracture prevention 
program (Chapter II). This program will focus on older patients with recent hip 
fracture and will include the development of a multidisciplinary pathway for the 
systematic referral of hip-fracture patients from the traumatology department to a 
geriatric assessment unit for evaluation and treatment of osteoporosis, a 
comprehensive geriatric assessment, fall evaluation and fall prevention. As this 
will be a 'surgeon-driven' referral, it is the aim of the program to increase 
compliance to osteoporosis treatment. The evaluation of the program will include 
the assessment of its clinical impact. 
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2) The development and the implementation of new surgical techniques to improve 
implant fixation in the osteoporotic femoral head by biomechanically testing new 
surgical techniques. First of all, the concept of the technique of implant 
augmentation will be biomechanically tested on a foam model (Chapter III).  
Secondly, the feasibility of the surgical technique will be tested on a cadaver 
model followed by biomechanical testing (Chapter IV). Finally, after clinical 
implementation of the technique and preliminary feedback, a study on cement 
localisation will be performed on a foam model (Chapter V). 
 
This research project will build on the existing research expertise of the Leuven 
University Center for Metabolic Bone Diseases (CMBD) in Leuven, Belgium, and the 
AO (Arbeitsgemeinschaft für Osteosynthesefragen) Research Institute in Davos, 
Switzerland. 
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Chapter I 
 
 
 The impact of care pathways for fragility hip fracture 
treatment on one-year mortality: 
 systematic literature review and meta-analysis 
  
 
 
 
This chapter is in preparation for publication: 
Sermon A, Herteleer M, Milisen K, Fieuws S, Vanhaecht K, Broos P, Richards R, 
Flamaing J. The impact of care pathways for fragility hip fracture treatment on one-
year mortality: systematic literature review and meta-analysis. 
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1. Abstract 
Background: Due to the increasing incidence of osteoporotic hip fractures, 
organizational improvement efforts are numerous. This evolution has lead to the 
development of clinical pathways for geriatric hip fracture treatment on the one hand 
and to the emergence of different types of co-managed care on the other hand. 
Besides a huge variety within the content of these programs, only short-term effects 
have been studied so far. It is the aim of the actual study to perform a systematic 
review of the literature on the long-term effects of clinical pathways for fragility hip 
fracture patients. 
 
Materials and methods: A systematic search of the Medline, Embase, CINAHL and 
the Cochrane Database was performed from 1995 until present. Two independent 
reviewers screened all articles on clearly defined inclusion and exclusion criteria for 
clinical pathways for fragility hip fracture patients. The one-year mortality rate was set 
as primary outcome parameter, the prescription of anti-osteoporosis medication and 
the effect of care pathways on recurrent fracture rate were set as secondary outcome 
parameters. 
 
Results: The literature search resulted in the selection of 11 studies of which four 
were randomized controlled trials and seven were non-randomized studies. A 
significant effect of clinical pathways for fragility hip fracture treatment on one-year 
mortality was found for non-randomized clinical trials and a positive but no significant 
effect was found for randomized controlled studies. 
In only two of the included studies compliance to osteoporosis treatment was 
incorporated as an outcome parameter and none of the included studies reported 
recurrent fracture rate. 
 
Conclusion: A positive effect on the one-year mortality could be observed for non-
randomized studies on care pathways for fragility hip fracture treatment. Although a 
similar effect could be observed for the randomized studies, formal evidence is 
lacking. Furthermore, no data about recurrence fracture rate and only very limited 
data on medical osteoporosis treatment could be found in the included studies. 
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2. Introduction 
During the last decades, big advances have been made in the organization of the 
care for fragility hip fracture patients. This is probably due to the increasing incidence 
of osteoporotic hip fractures and their devastating consequences for the individual 
patients and for society in general. Fragility hip fracture patients have a 5- to 8-fold 
increased risk of death in the three to six months following their fracture. It has been 
shown that this excess mortality persists over time and this for both women and men. 
It is not clear whether osteoporotic hip fracture patients suffer more from underlying 
frailty or whether the hip fracture on itself acts like a trigger inducing frailty.1 As our 
active aging population will continue to grow, the incidence of osteoporotic hip 
fractures and the economic consequences will do likewise. In Europe, there was an 
incidence of 3.5 million osteoporotic fractures generating an economic burden of € 37 
billion in 2010. It was calculated that these costs will increase with 25% in 2025.2 
These striking numbers lead to organizational improvement efforts in the care for 
fragility hip fracture patients. On the one hand, clinical pathways for geriatric hip 
fracture patients have been developed. Following the definition of Vanhaecht et al3, a 
clinical pathway is "a complex intervention for mutual decision making and 
organization of predictable care for a well-defined group of patients during a well-
defined period". Following the definition of Rotter et al4, clinical pathways are 
focusing on a specific patient population, bringing evidence to practice and trying to 
optimize clinical outcomes by a multidisciplinary team approach. 
On the other hand, the so-called co-managed care has become familiar to most 
trauma and orthopaedic surgeons. In a literature review, four types of co-managed 
care could be distinguished: an orthopaedic ward with geriatric consultant service on 
demand, an orthopaedic ward with a daily geriatric consultative service, a geriatric 
and rehabilitation ward with orthopaedic consultant service and an orthopaedic ward 
with integrated geriatric care.5 When studying these different types of co-managed 
care in detail, it becomes clear that the four models correspond more or less to the 
definition of a clinical pathway but that the fourth model "orthopaedic ward and 
integrated geriatric care" corresponds the best. 
The effects of co-managed care and of clinical pathways for fragility hip fracture 
treatment have been studied extensively. In a meta-analysis on clinical pathways for 
hip fracture patients, a significant influence on in-hospital complications like deep 
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venous thrombosis, pressure ulcer, surgical site infection and urinary tract infection 
was found while no significant influence on short term mortality could be 
documented.6 Clinical pathways tend to document and decrease in-hospital 
complications without influencing the length of stay.4 In a meta-analysis on 
orthogeriatric care models, it was concluded that orthogeriatric collaboration leads to 
a better in-hospital and long-term mortality as well.7 A weakness of this meta-
analysis however is the inclusion of three different types of orthogeriatric care, 
leading to heterogeneity. Only the “shared care” model, where both the geriatrician 
and the surgeon share the responsibility for the care of the patient, can be classified 
as a clinical pathway strictu sensu. 
Furthermore, most studies on clinical pathways for fragility hip fracture treatment only 
focus on short-term effects like length of stay and in-hospital or 30-day mortality. 
Only scarce and heterogeneous information is available on long-term mortality. 
However, in a review of the literature completed by a multidisciplinary meeting, 
orthopaedic surgeons, trauma surgeons and geriatricians from Europe, USA and 
Canada tried to generate consensus on which outcome parameters to use for the 
evaluation of orthogeriatric co-management. Long-term mortality was withheld as 
outcome parameter to be measured until one year after admission as was the 
medical treatment of the underlying osteoporosis.8  
Both primary (before the hip fracture) and secondary (after the hip fracture) decrease 
of bone mineral density (BMD) are associated with an increased mortality.9-11 The 
prescription and administration of anti-osteoporosis medication following a fragility 
fracture, should be included in the discharge planning as part of the comanaged care 
for fragility hip fracture patients. 
It is the aim of this systematic review to perform an extensive review of the available 
literature on the subject. The primary research question will be to evaluate the effect 
of clinical pathways for fragility hip fracture treatment on the 6 months and 1 year 
mortality. The secondary research questions will be to evaluate the post-fracture 
prescription of anti-osteoporosis medication and the effect of clinical pathways on 
recurrent fracture rate. Only primary studies on clinical pathways fulfilling the 
definition of Vanhaecht et al.3 will be included but secondary studies will be hand-
searched for relevant references. 
 
Chapter I: Literature review and meta-analysis 
26 
  
3. Materials and methods 
3.1. Data sources and searches 
A systematic search of the following databases was performed: Medline, Embase, 
CINAHL and The Cochrane Library. All databases were explored from 1995 until 
present.  
The following search terms were used: "hip fractures" (Medical Subject Heading 
(MeSH)), or "subtrochanteric fracture", or "trochanteric fracture", or  "intertrochanteric 
fracture", or "broken hip", or "osteoporotic fractures" (MeSH), AND "critical pathways" 
(MeSH), or "clinical pathway", or "referral pathway", or "care" and "pathway", or 
"referral and consultation", or "secondary care" (MeSH), or "orthogeriatric" and 
"team" and "work" (MeSH), or "geriatric assessment" (MeSH), or "orthogeriatric" and 
"comanagement", or "orthogeriatric" and "organization"  and "administration" (MeSH), 
or "management", or "disease management" (MeSH), or "patient care team" (MeSH), 
or "interdisciplinary health teams", AND "mortality" (MeSH), or "death rate", or "death 
rate constant", or "mortality decline", or "fatality rate", or "hospital mortality" (MeSH), 
or "survival rate" (MeSH), or "survival time", or "epidemiology", or "morbidity" 
(MeSH), or "patient readmission" (MeSH), or "reintervention", or "reinterventional", or 
"comorbidity" (MeSH). 
 
3.2. Inclusion and exclusion criteria 
Only primary literature (randomized controlled trials and non-randomized studies) 
was included. The selected literature had to be in English and had to involve co-
managed care for geriatric hip fracture patients corresponding to the definition of a 
clinical pathway (also termed a critical pathway, care path, or care map) of 
Vanhaecht et al.3 The main features of clinical pathways are the implementation of 
evidence based key interventions by a multidisciplinary team approach and the active 
follow-up of the process. A control group had to be included in the study and should 
consist out of geriatric hip fracture patients treated without co-managed care. The 
included studies had to provide information on the 6 months or one-year mortality 
and were subsequently checked for medical osteoporosis treatment or fracture 
recurrence rate within the first year following the fracture.  
Studies were excluded if they met another research design or covered a different 
setting. Articles were excluded if they were published before 1995 or if they included 
Chapter I: Literature review and meta-analysis 
27 
  
patients younger than 60. We decided not to include secondary literature (review 
articles and meta-analyses) but references of all included studies and of secondary 
studies were hand-searched for additional publications. 
 
3.3. Study selection 
One reviewer (H.M.) screened all titles and keywords of the retrieved studies to 
assess their eligibility according to the above-mentioned inclusion and exclusion 
criteria. Articles that did not meet the inclusion criteria were excluded during this 
phase. The abstracts of the remaining articles were subsequently screened by two 
reviewers (H.M. & S.A.). Studies were excluded if the abstract did not meet the 
inclusion criteria. Of the remaining studies, the full text articles were examined by 
both reviewers. Studies not dealing with a clinical pathway on geriatric hip fracture 
treatment, were excluded. Disagreements were resolved by discussion until 
consensus was obtained. 
 
3.4. Methodological quality assessment 
To assess the methodological quality of the included non-randomized studies, the 
Newcastle-Ottawa scale (http://www.ohri.ca/programs/clinical_epidemiology/oxford. 
asp)12 was used. A maximum of 9 stars could be provided to each study, evaluating 
patient selection, comparability of study groups and assessment of outcome. 
The results are shown in Table 1.  A maximum of 9 stars could be afforded to each 
study, evaluating patient selection (4 items, maximum of 4 stars), comparability of 
study groups (2 items, maximum of 2 stars) and assessment of outcome (3 items, 
maximum of 3 stars). 
 
Study Selection Comparability Outcome Stars (total) 
Barone (14) ** * ** 5 
Cogan (20) *** ** ** 7 
Leung (21) **** * ** 7 
Koval (22) **** ** ** 8 
Wagner (23) **** - ** 6 
Dy (24) ** - ** 4 
Adunsky (25) **** - ** 6 
 
Table 1: Quality assessment of non-randomized studies using the Newcastle-Ottawa 
     scale 
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3.5. Care pathway evaluation 
The full text of all possibly relevant articles was checked for the definition of a clinical 
pathway, using the criteria of Vanhaecht et al.3 Primarily, at least two or more 
evidence-based key interventions concerning the pre-operative, intra-operative or 
postoperative care had to be included. Secondly, a multidisciplinary team approach 
had to be present with shared responsibility for the osteoporotic hip fracture patients 
by surgeons and geriatricians, so all models based on consultancy were excluded.  
Finally, an evaluation of the pathway had to be performed by the presence of a 
control group. If an article fulfilled all of the above mentioned criteria, it was included 
in the meta-analysis, even if it was not literally called a clinical pathway.  
 
3.6. Data extraction and statistical analysis 
The following data were extracted from each study: study design, time of follow-up, 
number of included patients at start of the study, number of included patients at 6 
months, number/percentage of deceased patients at 6 months, number of included 
patients at 12 months, number/percentage of deceased patients at 12 months, 
number/percentage of fracture recurrences at 12 months, and medical osteoporosis 
treatment prescribed at discharge: type of medication and number of patients 
discharged with a prescription.  
Odds ratios comparing the 12-month mortality have been reported for the various 
studies. Depending on the study, the reported 12-month mortality referred to crude 
numbers (numerator and denominator), a crude percentage or a percentage derived 
from a Kaplan-Meier curve. As the 12-month mortality referred to crude numbers, a 
crude percentage or a percentage derived from a Kaplan-Meier curve, the analysis 
as such is a simplification since drop-out is not taken into account.  For the Kaplan-
Meier estimates, the information on the actual risk set is missing. For studies 
reporting crude numbers or percentages, the number of patients at inclusion is used 
as denominator. In case no data were available for the 12-month mortality, the 6-
month mortality has been used; this was done for 1 study.13 Further, for the study of 
Barone et al.14, both control groups (before and after) were combined into one group. 
A meta-analysis has been performed separately for non-randomized and randomized 
studies. Observed differences in effect size between the studies reflect true variability 
(between-study variability or heterogeneity) and sampling variability (within-study 
variability).  
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Heterogeneity was quantified by the I² statistic15 which is the percentage of total 
variation in study estimates that is due to heterogeneity and tested by Cochran’s X²-
test. The random-effects approach of DerSimonian and Laird16 was used to obtain a 
pooled estimate as a weighted average of the study-specific estimates. 
 
4. Results 
4.1. Study selection 
The results of the search strategy are summarized as a flowchart in figure 1. 
The preliminary search resulted in 1,479 citations of which 233 were eliminated as 
duplicates. Of the 1,246 remaining studies, 1,203 were excluded after title and / or 
abstract screening based on the in- and exclusion criteria. The 43 remaining studies 
were considered for full text reading. 32 studies were excluded because they did not 
answer to the definition of a clinical pathway. Finally, 11 studies were retained for 
statistical analysis, of which four were randomized controlled studies13,17-19 and seven 
non-randomized studies.14, 20-25  
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  Figure 1: Study selection 
        (RCT = Randomized Controlled Trial, NRS = Non-Randomized Study) 
 
 
 
 
 
 
 
 
 
Overall identified publications based on 
title and abstract: N=1,479  
  
Possibly relevant publications: N=1,246  
 
  
  
Excluded after full text screening: N=32  
 
  
  
 Publications included in systematic 
review: N=11 (4 RCT, 7 NRS )  
 
  
  
Excluded (inclusion/exclusion criteria) on 
title and / or abstract screening: N=1,203 
N=1203  
 
  
   Studies considered for inclusion N=43  
 
  
  
 Excluded publications (duplicates): N=233  
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4.2. Descriptive information  
The descriptive information on outcome of the included studies is summarized in 
Table 2. Of the 11 included studies, four were randomized controlled trials13,17-19 and 
seven were non-randomized studies.14,20-25 The follow-up time of all studies was 12 
months, except for the study of Naglie et al.13 with a follow-up time of 6 months. All 
studies reported on mortality. Only two studies reported on osteoporosis 
treatment20,23 and in none of the studies recurrent fractures were mentioned. 
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Study SD FUTime N1 Ndeath1 %death1 N0 Ndeath0 %death0 OstMed %med1 %med0 Nrecur1 Nrecur0 
Barone
14
  NRS 12 252  25.0 567  34.3      
Cogan
20
  NRS 12 98  34.0 103  45.0 Bisph  
Ca 
54 
60 
1 
2 
  
Leung
21 
NRS 12 278 32  270 55       
Koval
22 
NRS 12 747 66  318 45       
Wagner
23 
NRS 12 92  13.0 183  13.0 Ca + vit D 100 5   
Dy
24 
NRS 12 34 9  40 9       
Adunsky
25 
NRS 12 847  14.8 2,267  17.3      
Vidan
17 
RCT 12 155  18.9 164  25.3      
Day
18 
RCT 12 38    8.0 33  13.0      
Shyu
19 
RCT 12 79 4  80 6       
Naglie
13 
RCT 6 141 17  138 21       
 
Table 2: Descriptive information of the included studies  
(SD = study design (NRS = non-randomized study, RCT = randomized controlled trial); FUTime = follow-up time in months; N1 = number of included patients 
in the intervention group; Ndeath1 = number of deceased patients in the intervention group at the end of the study; %death1 = percentage of deceased 
patients in the intervention group at the end of study; N0 = number of included patients in the control group; Ndeath0 = number of deceased patients in the 
control group at the end of the study; %death0 = percentage of deceased patients in the control group at the end of study; OstMed = type of anti-osteoporosis 
medication provided to the included patients (Bisph = Bisphosphonate, Ca = calcium, vit D = vitamin D); %med1 = percentage of patients receiving medical 
osteoporosis treatment in the intervention group; %med0 = percentage of patients receiving medical osteoporosis treatment in the control group; Nrecurr1 = 
number of recurrent fractures in the intervention group at the end of the study; Nrecur0 = number of recurrent fractures in the control group at the end of the 
study) 
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4.3. Mortality 
The results are summarized in Table 3 and Figure 2 for the non-randomized studies 
and in Table 4 and Figure 3 for the randomized studies. Odds ratios (intervention 
versus control) comparing the 12-month mortality have been reported for the various 
studies. The meta-analysis of the non-randomized studies (Figure 2 and Table 3) 
shows a significant difference in mortality at 12 months in favour of the intervention 
group. 
The meta-analysis of the randomized studies (Figure 3 and Table 4) shows also a 
difference in mortality at 12 months in favour of the intervention group, although non 
significant. For the non-randomized studies, there was a non significant between-
study heterogeneity (I2 = 15.2%, Cochran's Q = 7.08, df = 6, p = 0.3137). For the 
randomized studies, there was no between-study heterogeneity (I2 = 0.0%, 
Cochran's Q = 0.09, df = 3, p = 0.9926). 
 
4.4. Osteoporosis treatment 
Only in two studies20,23 information was provided about the prescription of medical 
osteoporosis treatment at discharge. In the study of Cogan et al.20, 54% of the 
patients in the intervention group received a prescription for bisphosphonates at 
discharge compared to 1% of the patients in the control group. 60% of the patients in 
the intervention group received a co-prescription for calcium compared to 2% in the 
control group. In the study of Wagner et al.23, calcium and vitamin D was prescribed 
at discharge to 100% of patients in the intervention group compared to 5% in the 
control group. Because of the lacking of information about osteoporosis treatment in 
the other studies, no meta-analysis on this subject could be performed. 
 
4.5. Recurrent fractures 
In none of the included studies information was provided on recurrent fractures within 
the first year following the initial fracture. If information on readmissions was included 
at all, only medical reasons for readmissions were reported. 
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Figure 2: Odds ratios comparing 12-month mortality for the non-randomized studies. The combined effect size is given at 
the bottom of the figure. 
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 Intervention  Control  
Study  N N events %  N N events %  Odds ratio (95%CI) 
Barone  252 63 25.0%  567 195 34.4%  0.636 (0.455;0.812) 
Cogan  98 33 33.7%  103 46 44.7%  0.629 (0.355;0.957) 
Leung  278 32 11.5%  270 55 20.4%  0.508 (0.317;0.720) 
Koval  747 66 8.8%  318 45 14.2%  0.588 (0.393;0.791) 
Wagner  92 12 13.0%  183 24 13.1%  0.994 (0.473;1.715) 
Dy  34 9 26.5%  40 9 22.5%  1.240 (0.428;2.708) 
Adunsky  847 125 14.8%  2267 392 17.3%  0.828 (0.665;0.973) 
  . . .  . . .   
Meta-analyses:  . . .  . . .   
Fixed effects estimate  . . .  . . .  0.715 (0.617;0.828) 
Random effects estimate  . . .  . . .  0.702 (0.591;0.833) 
Evaluation between-study heterogeneity: I²=15.2%, Q=7.08, df=6, p=0.3137 
I²=percentage of variation in study estimates due to heterogeneity. Q=Cochrans Q statistic.Df=Degrees of Freedom for  
heterogeneity test. 
Random Effects Analysis: DerSimonian and Laird method. 
 
 Table 3: Odds ratios comparing 12-month mortality for the non-randomized studies. 
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Figure 3: Odds ratios comparing 12-month mortality for the randomized studies. The combined effect size is given at the 
bottom of the figure. 
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 Intervention  Control  
Study  N N events %  N N events %  Odds ratio (95%CI) 
Vidan  155 29 18.7%  164 41 25.0%  0.690 (0.404;1.024) 
Day  38 3 7.9%  33 4 12.1%  0.621 (0.129;1.977) 
Shyu  79 4 5.1%  80 6 7.5%  0.658 (0.178;1.716) 
Naglie  141 17 12.1%  138 21 15.2%  0.764 (0.384;1.266) 
  . . .  . . .   
Meta-analyses:  . . .  . . .   
Fixed effects estimate  . . .  . . .  0.706 (0.478;1.042) 
Random effects estimate  . . .  . . .  0.706 (0.478;1.042) 
Evaluation between-study heterogeneity: I²=0.0%, Q=0.09, df=3, p=0.9926 
I²=percentage of variation in study estimates due to heterogeneity. Q=Cochrans Q statistic.Df=Degrees of Freedom for 
heterogeneity test. 
Random Effects Analysis: DerSimonian and Laird method. 
 
 Table 4: Odds ratios comparing 12-month mortality for the randomized studies
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5. Discussion 
5.1. Methodological considerations 
The literature search resulted in the selection of 11 studies of which four were 
randomized controlled trials and seven were non-randomized studies. Because of 
this small number of studies retrieved, it was decided to include all the withheld 
studies in the review but performing a separate meta-analysis for the randomized 
and non-randomized studies as non-randomized studies include a bigger risk of bias. 
A possible explanation for the absence of randomized controlled studies on the 
subject could be the existing evidence of the studied intervention.26 As there is 
evidence about the short term advantages (e.g. in-hospital mortality, pressure sores, 
surgical site infections, medical complications) of clinical pathways for fragility hip 
fracture treatment6,27 and of orthogeriatric care models7, it would be non ethical to 
exclude a patient group from this intervention by performing randomized controlled 
trials evaluating long-term effects. Another explanation especially for the missing 
data on long-term mortality in general, could be the difficulty of long-term follow-up of 
a geriatric patient population. Despite the inclusion of non-randomized studies in a 
separate meta-analysis however, heterogeneity between these studies was low as 
was quantified by the I2 statistics of Higgins and Thompson.15 
As non-randomized studies contain a larger risk for bias, a methodological quality 
check was performed on the seven included non-randomized studies by using the 
Newcastle-Ottawa scale.12 As summarized in Table 1, selection bias was rather low 
for most studies as was reporting bias (evaluated as "outcome"). Comparability 
however was difficult to assess because no information on comparability of study 
cohorts was provided in three of the seven included studies.23-25 On the other hand 
because the effect size of the meta-analysis was measured as odds ratio and not as 
relative risk, the influence of possible differences in study populations between 
studies was ruled out presuming that intervention and control groups within each 
study are comparable. 
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5.2. Considerations on the structure and the content of the clinical pathways 
of the included studies 
Concerning the structure of the clinical pathways included in this literature study, 
strong selection criteria were used. These selection criteria give our analysis an  
added value compared to previously performed literature studies including different 
types of interventions, making pooling of the results much more difficult. Studies 
could only be included in our analysis if the described pathway comprised two or 
more evidence based key-interventions, if a multidisciplinary team approach was 
used and if there was an active follow-up of the process. By doing this, only 
evidence-based, multidisciplinary and controlled processes were included, allowing 
us to pool the results, independently from the name given to the pathway or care 
process. The analysis of the included studies indeed revealed a huge diversity in 
names given to the interventions: four studies mentioned “orthogeriatric 
service”14,20,21,23, three studies talked about “multi- or interdisciplinary care”17,19,13, 
three studies used a unique name: “comanaged care”24, “liaison team”18, 
"comprehensive geriatric hip fracture unit"25 and only in one study the intervention 
was called a “clinical pathway”.22 
By the use of clear selection criteria however, it became clear that the content of the 
interventions is more important than the name given to it. Consequently, it was not 
necessary for a study to be called a "clinical pathway" to be included in this meta-
analysis. 
Concerning the content of the clinical pathways, a big variability could be observed. 
At first sight, this finding could make it more difficult to draw any conclusion.  A 
detailed analysis of the reported key-interventions however, enabled us to sort all 
interventions in one of the following three groups: inpatient care with special attention 
to medical comorbidities (preoperatively, peroperatively and postoperatively), 
rehabilitation and discharge planning. 
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5.3. Considerations on the effects of clinical pathways 
This study revealed a significant effect of clinical pathways for fragility hip fracture 
treatment on the long-term mortality for non-randomized studies only. For the 
randomized controlled trials included in the study however, a positive but not 
significant effect could be found on the 1-year mortality. This is a new finding besides 
the already known short term effects on length of stay and in-hospital 
complications.6,27 This should encourage any surgeon treating osteoporotic hip 
fracture patients to go for well-organized,  interdisciplinary care for this frail patient 
population. Before, the beneficial effects of multidisciplinary and organized care for 
geriatric patients have only been proven on dedicated geriatric wards and Geriatric 
Assessment and Management Units (GEMU). A Cochrane review could show a 
significant increase in survival after one year if comprehensive geriatric assessment 
was provided on a dedicated geriatric ward28. A meta-analysis on the effects of 
GEMU could show significant effects on functional decline at discharge and on 
institutionalization after one year in favour of GEMU compared to usual care. No 
significant effect could be shown on mortality at any specific time point.29 
None of the included studies mentioned recurrent fractures. In literature however, 
very high numbers of recurrent osteoporotic hip fractures can be found: the 10-year 
probability of a recurrent hip fracture after a primary osteoporotic hip fracture reaches 
nearly 25%.30,31 Furthermore, patients with recurrent osteoporotic fractures not only 
suffer from the morbidity associated to the secondary fracture, but they also 
experience an associated high mortality.31 
Finally, only in two studies medical osteoporosis treatment was mentioned. The 
effectiveness however of anti-resorptive therapy on the prevention of recurrent hip 
fractures as well as on the mortality in general, has been proven.32,33 Despite this 
finding, the long-term compliance to anti-osteoporosis treatment is low34,35, as is 
confirmed in a study on the Belgian situation.34 
The positive effect of clinical pathways for fragility hip fracture treatment on in-
hospital complications and on both short- and long-term mortality, should encourage 
surgeons to start medical osteoporosis treatment after a first fragility fracture. In the 
light of the multidisciplinary care and follow-up of the patients, any treating physician 
should encourage long-term compliance to this treatment. 
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5.4. Limitations of the actual study and considerations for further research 
The actual review of the literature and meta-analyses have several limitations. 
First of all, only a small number of studies could be found. The study design of these 
studies (four randomized controlled trials and seven non-randomized studies) forced 
us to perform two separate meta-analyses. Only for the non-randomized studies, a 
significant effect of clinical pathways on one-year mortality could be shown whereas 
a positive although non-significant effect could be shown for the randomized 
controlled studies. As only four randomized controlled studies could be included and 
the total number of patients included in the randomized controlled studies is much 
lower (828 versus 6096 in the non-randomized studies), formal evidence is lacking 
for the randomized studies although a similar positive effect of care pathways could 
be observed on the one-year mortality. Furthermore, no data about recurrence 
fracture rate and only very limited data on medical osteoporosis treatment could be 
found in the included studies. Further research on this subject is needed: at first to 
rule out if this is a reporting problem or really a missed chance for secondary fracture 
prevention. In any way, attention should be given to include refracture prevention in 
clinical pathways for geriatric hip fracture treatment. 
 
6. Conclusion 
A meta-analysis performed on clinical pathways for fragility hip fracture treatment 
showed a significant effect on 1 year mortality for non-randomized clinical trials and a 
positive as well but non significant effect for randomized controlled studies. 
In only two of the included studies compliance to osteoporosis treatment was 
incorporated as an outcome parameter and none of the included studies reported 
recurrent fracture rate. 
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Chapter II 
 
 
The impact of a traumatologic-geriatric post-fracture 
program for osteoporotic hip fracture patients 
 
 
 
 
This chapter is in preparation for publication: 
Sermon A, Boonen S, Michiels T, Broos P, Richards R, Flamaing J. The impact of a 
traumatologic-geriatric post-fracture program for osteoporotic hip fracture patients. 
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1. Abstract 
Objectives: To assess the impact of a traumatologic-geriatric fracture prevention 
program on process and outcome parameters in osteoporotic hip fracture patients. 
 
Setting: Department of Traumatology and Center for Metabolic Bone Diseases, 
University Hospitals Gasthuisberg, Leuven, Belgium. 
 
Design: Retrospective study performed by patient chart analysis. The included 
patients are all 65 years of age or older and were admitted to the Department of 
Traumatology with an osteoporotic hip fracture. The traumatologic-geriatric hip 
fracture program consisted of administration of calcium and vitamin D supplements 
and referral to the Center for Metabolic Bone Diseases to assess the osteoporosis 
risk and to administer bisphosphonates if indicated. Furthermore, patients, their 
family and general practitioners were informed about the importance of osteoporosis. 
Two groups were created: an intervention group of patients subjected to the program 
(n=193) and a historical control group treated by standard care (n=253). 
Demographic, process and outcome parameters for both groups were compared. 
 
Main Measurements: The following process indicators were studied: administration 
of calcium, vitamin D and bisphosphonates; information to patients, their relatives 
and general practitioners; referral to geriatric one day clinic or outpatient consultation. 
Furthermore the following outcome parameters were studied: time until new fracture 
and mortality within the first year. 
 
Results: While comparing both groups, statistic significant differences for all process 
indicators were observed. However, no statistically significant changes in main 
outcome measurements were observed. 
 
Conclusions: In this study, a traumatologic-geriatric post-fracture program aiming at 
the prevention of osteoporotic recurrent fractures in geriatric hip fracture patients was 
not associated with a significant reduction in fracture recurrence and mortality within 
the first year after the fracture. Nevertheless, a significant difference was observed 
between the two study groups for all process indicators. How to organize a post-hip 
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fracture program with an impact on fracture recurrence and mortality, needs further 
investigation. 
 
2. Introduction 
During the last decades, a worldwide increase in osteoporosis related hip fractures 
has been noticed.1 For the European Union, there is a yearly incidence of about  
620,000 hip fractures in women and men. In Belgium, the yearly incidence is about  
15,000.2 Due to the aging of our population and to the higher activity level of the 
older persons, a further increase of the number of hip fractures is expected.3 
Besides a tremendous increase in health care related costs, the consequences of hip 
fractures for the individual patients are devastating.4 There is a significant decline in 
the ability to perform activities of daily living for most of the patients and up to 10 to 
20% of hip fracture patients are not able to return to their previous residence and 
need some form of assisted care. Furthermore, the mortality rate in the year following 
a hip fracture rises to 30%.5 Moreover, recent studies show that this excess mortality 
persists over time for both women and men: the risk of death in the 10 to 15 years 
following a hip fracture is 3 to 4 times as high as in the non-hip fracture patient 
population.6,7 It has become clear that a hip fracture is a sign of frailty: hip fracture 
patients often suffer from underlying comorbidities resulting in a limited functionality 
and health prior to the fracture.8 There is no doubt that the concomitant management 
of these comorbidities has an important influence on the outcome of elderly patients 
with hip fractures.9 Due to the amelioration of the surgical techniques for treating hip 
fractures, good medical aftercare has become as important as good operative 
fracture treatment. Finally, next to medical complications, hip fracture patients suffer 
from an increased bone degradation with an inherent risk of recurrent fractures as 
well.10 
During the last years, the beneficial effect of care pathways for fragility hip fracture 
treatment has become clear. As most of the orthogeriatric fracture care programs 
comprise a systematic approach of evidence-based key interventions in a 
multidisciplinary and controlled way, they can be called care pathways following the 
definition of Vanhaecht et al.11 Most studies on care pathways however, prove their 
influence on short-term effects like in-hospital complications, length of stay and 30-
days mortality.12,13 In a recent systematic review of the literature and meta-analysis 
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(Chapter I) however, the beneficial effect of care pathways on the 1-year mortality 
could be demonstrated. On the other hand, no data about recurrence fracture rate 
and only very limited data on medical osteoporosis treatment could be found in the 
included studies. Too little attention has been given to secondary fracture prevention 
as 2-6 % of hip fractures are recurrent fractures.7 
From large-scale studies, the beneficial effect of pharmacological prevention on 
recurrent hip fractures has become clear. In the "recurrent fracture trial", the authors 
could show a reduction in fracture risk as well as in mortality in a population of 
previous hip fracture patients by the once-yearly intravenous administration of 
zoledronic acid.14 Despite existing guidelines on medical osteoporosis treatment15,16 , 
implementation in clinical practice is suboptimal.17 For the Belgian situation, it has 
been shown that only a minority of hip fracture patients take anti-resorptive 
medication after a fragility hip fracture. Of those who initiated treatment however, 
adherence diminishes over time and remains suboptimal.18 This finding corresponds 
to previous studies, proving low compliance to anti-resorptive medication.19,20 
The current study evaluates the introduction of a clinical pathway for medical 
osteoporosis treatment and prevention of recurrent fractures. In the Department of 
Traumatology of the University Hospitals Leuven, Belgium, a protocol-driven 
comanaged care for fragility hip fracture patients was implemented. This program is 
characterised by a multidisciplinary approach of the geriatric hip fracture patient from 
the moment of admission to discharge. The main objective is a successful treatment 
of the geriatric hip fracture patient by providing the best surgical fracture care as well 
as correct and timely treatment of the underlying comorbidities. With the 
development and the implementation of a traumatologic-geriatric post-fracture 
program, the treatment of the underlying osteoporosis was included in the care for 
the geriatric hip fracture patient. This care program consists of a surgeon-driven 
integrated pathway of clinical referral and care for osteoporotic hip-fracture patients. 
By a systematic referral of all fragility fracture patients to the Center for Metabolic 
Bone Diseases (CMBD) of the UZ Leuven, the underlying osteoporosis is evaluated 
and managed with pharmacological as well as non-pharmacological preventive 
measures. The objective of the program is to decrease the number of secondary 
osteoporotic fractures. The implementation of this post-fracture program was started 
in January 2010. This study compares the process and outcome parameters of 
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patients included in the traumatologic-geriatric post-fracture program with a historical 
study group. 
 
3. Materials and methods 
3.1. Introduction and implementation of clinical pathway 
The clinical pathway "prevention of recurrent fractures after fragility hip fracture" was 
introduced in the Department of Traumatology of the University Hospitals Leuven 
from January 2010 on. The pathway was based on a collaboration of the 
Traumatology Department and the CMBD. The authors SB and AS developed the 
clinical pathway in consensus following the actual available evidence on the subject. 
The inclusion criteria are as follows: patients of 65 years of age or older who sustain 
a fragility hip fracture and who are able to come to the CMBD on an ambulatory 
base. The following exclusion criteria are used: patients who are younger than 65 
years, who sustained a non-fragility fracture (e.g. pathologic fracture, polytrauma,...) 
or who are not able to come to the CMBD on an ambulatory base. Patients are 
included in the pathway as soon as they are hospitalized on the traumatology 
department for the treatment of a fragility hip fracture. 
The following key interventions are performed after inclusion in the pathway:  
 The administration of calcium (1000 mg) and vitamin D (800 IU 
 (International Units)). 
 The systematic referral to the CMBD for the evaluation and treatment of  
underlying osteoporosis. 
 Providing information about the clinical pathway to the patient, her / his  
family and general practitioner. 
Figure 1 displays a flow-chart of the clinical pathway. 
Patients under the age of 75 visit the outpatient clinic of the CMBD where the 
following interventions are performed: a comprehensive geriatric assessment and a 
DEXA (Dual Energy X-Ray Absorptiometry)-scan followed by pharmacological 
osteoporosis (when present) treatment and non-pharmacological fall prevention 
measurements.  
Patients above 75 years receive the interventions of the CMBD through a visit of the 
geriatric day-hospital, as this constitutes a more comfortable setting adjusted to their 
age-related physical and mental restrictions.  
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Here a comprehensive geriatric assessment is performed and intravenous anti-
osteoporosis therapy is administered if there are no contra-indications. A DEXA-scan 
is performed to determine the baseline-value of the underlying bone quality. 
Furthermore non-pharmacological fall prevention measurements are administered. 
 
 
 
Figure 1: Flow-chart of clinical pathway 
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3.2. Evaluation of clinical pathway 
To evaluate the clinical pathway, a retrospective study was performed by patient 
chart analysis. Two study groups were created: an intervention group of patients 
included in the clinical pathway (patients treated for a fragility hip fracture between 
April 1st, 2010 until September 30th, 2011; n=193) and a historical control group 
treated by standard care before the introduction of the clinical pathway (patients 
treated for a fragility hip fracture from April 1st, 2008 until September 30th 2009; 
n=253). Demographic, process and outcome parameters for both groups were 
compared. A retrospective review of patients' charts was performed with a 
standardized form to collect the required data from the day of the fracture to one year 
postoperatively. In those cases where the data could not be retrieved from the 
patients' charts, a document was sent to the patients, asking them to fill in the 
missing information. Data were collected on demographic characteristics (age and 
sex), comorbidities (ASA (American Society of Anaesthesiologists)-score), fracture 
type (fracture classification and preceding fractures), treatment type and duration of 
follow-up. Furthermore the following process indicators were collected: start of 
calcium and vitamin D administration during the hospital admission following the hip 
fracture, referral to the CMBD and information provided to the patient, his / her family 
and the general practitioner. Finally, the following outcome parameters were 
collected one year after sustaining the fracture: complications, readmissions, 
reinterventions, subsequent hip fracture, mortality. All data were handled 
anonymously. The study was approved by the Ethical Committee of the University 
Hospitals Gasthuisberg (study number S55746, Belgian number B322201318524). 
3.3. Statistical analysis 
Fisher's exact test was used to compare categorical and ordinal variables between 
groups and Mann-Whitney U test was used to compare continuous variables 
between groups. Curves for overall survival, time until readmission and time until a 
new fracture were constructed using Kaplan-Meier estimates and compared between 
groups with a log-rank test. Only events within one year were considered. P-values 
smaller than 0.05 were considered significant. All analyses have been performed 
using SAS software, version 9.2 of the SAS System for Windows. 
 
 
Chapter II: Traumatologic-geriatric post-fracture program 
53 
  
4. Results 
4.1. Clinical pathway implementation 
As described in the materials and methods section, the clinical pathway was 
developed by the authors SB and AS following evidence based key interventions. 
The pathway was implemented on the Traumatology Department from January 2010 
on. The following people were involved in the application of the clinical pathway: 
 All surgeons, assistants and trainees involved in fragility hip fracture 
treatment: they include the patients in the clinical pathway as soon as they 
are hospitalized on the ward, either pre - or postoperatively, following the 
well-defined in- and exclusion criteria. Furthermore, they prescribe calcium 
and vitamin D to all included patients and inform the patients, their family and 
general practitioner about underlying osteoporosis, risk for subsequent 
fractures, importance of medical treatment and referral to the CMBD. 
 Clinical pharmacist working on the ward: he or she performs follow-up and 
adjustment of the prescribed drugs when needed (calcium and vitamin D and 
other anti-osteoporosis treatment if preoperatively started) and checks renal 
function (minimum clearance of 35 ml/min needed for the safe administration 
of intravenous anti-osteoporosis treatment). 
 Nurses on the ward: they administer calcium and vitamin D, and provide 
information to the patient and her / his family about the clinical pathway. 
 Secretary on the ward: she makes the appointment for referral to the CMBD 
approximately six weeks postoperatively. 
 Doctors and nurses working at the CMBD: they perform the following 
interventions: 
o For the patients above the age of 75: a comprehensive geriatric 
assessment, a DEXA-scan to establish a reference value of the bone 
quality, the administration of intravenous anti-osteoporosis therapy 
after control of the renal function and a fall risk assessment. 
o For the patients below the age of 75: a comprehensive geriatric 
assessment, a DEXA-scan, start of specific anti-osteoporosis 
medication if T-value < -2.5 and a fall risk assessment. 
All co-workers involved in the implementation and execution of the clinical pathway 
were informed by SB and AS by means of information sessions and consultable 
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power point presentations. Two months after the introduction of the clinical pathway 
an evaluation meeting was organized by SB and AS with representatives of all co-
workers involved. Some fine-tuning and practical adaptations were made to the 
pathway. Hereafter, the pathway was implemented in the Traumatology Department. 
 
4.2. Evaluation 
The following data were extracted from the patients' charts: 
a. General characteristics of the included patients 
 A summary of patient characteristics can be found in Table 1. The 
intervention and the control group were comparable concerning age, gender, 
ASA-classification, fracture type, fracture treatment and follow-up time. The 
mean age of the patients was 81.2 (± 6.57) in the control group and 81.1 (± 
6.87) in the intervention group. The male/female ratio was identical in both 
groups (± 1/3). The ASA-classification was comparable in both groups with 
most of the patients being ASA 2 or 3. The fracture classification was similar 
in both study groups with a nearly equal distribution of intra- and 
extracapsular fractures. The same equal distribution in treatment type could 
be noticed with slightly higher numbers of osteosynthesis than prostheses in 
both study groups. The mean follow-up time was 10 months in both study 
groups with a follow-up of one year in about 78% of the patients in both study 
groups as well. Only the number of preceding fractures was significantly 
higher in the intervention group than in the control group (52 compared to 24, 
p<0.001). 
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 CHARACTERISTIC CONTROL INTERVENTION P-VALUE 
  GROUP GROUP  
  (N = 253) (N = 193)  
 Age, mean ± standard 81.2 ± 6.57 81.1 ± 6.87 0.914 
  deviation      
 Gender, n (%)     0.914 
  Female 187 (73.91%) 141 (73.06%)  
  Male 66 (26.09%) 52 (26.94%)  
 ASA-score, n (%)     0.653 
  1 13 (5.14%) 9 (4.66%)  
  2 137 (54.15%) 94 (48.70%)  
  3 97 (38.34%) 85 (44.04%)  
  4 6 (2.37%) 5 (2.59%)  
 Fracture type, n (%)     0.849 
  Intracapsular 130 (51.38%) 101 (52.33%)  
  Extracapsular 123 (48.62%) 92 (47.67%)  
 Treatment type, n (%)     0.499 
  Osteosynthesis 149 (58.89%) 107 (55.44%)  
  Prosthesis 104 (41.11%) 86 (44.56%)  
 Preceding fracture, n (%)     < 0.001 
  Yes 24 (9.49%) 52 (26.24%)  
  No 229 (90.51%) 141 (73.06%)  
 Follow-up      
  Time (months), mean  10.0 ± 3.86 10.1 ± 3.74 0.810 
  ± standard deviation    
  One year, n (%) 196 (77.47%) 151 (78.24%) 0.909 
 
Table 1: Patient characteristics 
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b. Process parameters 
 An overview of the process parameters can be found in Table 2. 
 All process parameters were significantly better (all p < 0.001) in the 
intervention group than in the control group. More patients received anti-
osteoporotic medication at discharge in the intervention group. Ninety-five % 
of patients in the intervention group received calcium and vitamin D 
compared to 38% in the control group. Furthermore, 61% of the patients in 
the intervention group received an anti-osteoporosis treatment in addition to 
calcium and vitamin D compared to 17% in the control group. A detailed 
analysis of patients' charts showed that this were mainly bisphosphonates. 
Usually, calcium, vitamin D and anti-osteoporosis medication were started 
postoperatively. 
 Significantly more patients from the intervention group were referred to the 
CMBD compared to the control group, Significantly more of the referred 
patients in the control group (100% or all of the referred patients) than in the 
intervention group (71%, p < 0.001) presented themselves at the CMBD. The 
time interval between hospitalization and referral to the CMBD was 
comparable in both study groups (p = 0.090). There was no difference in 
numbers of DEXA-scans performed between the control and the intervention 
group (p = 0.809). Finally, significantly more general practitioners of patients 
in the intervention group than in the control group were informed about 
postoperative care and follow-up details, with 90% (p < 0.001) of the general 
practitioners of the intervention group being informed. 
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 PROCESS PARAMETER CONTROL INTERVENTION P-VALUE 
  GROUP GROUP  
  (N = 253) (N = 193)  
 Osteoporosis treatment, n (%)     <0.001 
  No 155 (61.26%) 9 (4.66%)  
  Yes 98 (38.74%) 184 (95.34%)  
 -  Calcium + Vitamin D, n (%)     <0.001 
  No 156 (61.66%) 10 (5.18%)  
  Preoperatively started 51 (20.16%) 30 (15.54%)  
  Postoperatively started 46 (18.18%) 153 (79.27%)  
 -  Other*, n (%)     <0.001 
  No 210 (83.00%) 75 (38.86%)  
  Preoperatively started 24 (9.49%) 17 (8.81%)  
  Postoperatively started 19 (7.51%) 101 (52.33%)  
 Referral to CMBD, n (%)     <0.001 
  No 224 (88.54%) 14 (7.25%)  
  Yes 29 (11.46%) 179 (92.75%)  
 Compliance with referral, n (%)     <0.001 
  Non compliance 0 (0.00%) 52 (29.05%)  
  Compliance 29 (100.00%) 127 (70.95%)  
 DEXA     0.809 
  No 201 (80.08%) 156 (81.25%)  
  Yes 50 (19.92%) 36 (18.75%)  
 Information to GP, n (%)     <0.001 
  No 247 (97.63%) 20 (10.36%)  
  Yes 6 (2.37%) 173 (89.64%)  
 
Table 2: Process parameters  
   (*mainly antiresorptive therapy) 
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c. Outcome parameters 
 An overview of the complications and reinterventions is provided in table 3. 
There were significantly more general complications in the intervention group 
compared to the control group (47.15% compared to 34.39%, p = 0.008).  
There were no differences in the number of local complications between the 
intervention and the control group (13.99% compared to 10.67%, p = 0.307). 
There were significantly more reinterventions in the intervention group 
compared to the control group (8.81% compared to 3.95%, p = 0.044). 
 The time free from new fracture is displayed as a Kaplan-Meier estimate in 
Figure 1. In the year following the fracture, there were less patients with a 
recurrent fracture in the intervention than in the control group, however this 
difference was not significant (p = 0.3984). After eliminating the patients with 
a preceding fracture, there was no difference in time free from new fracture 
between the intervention and the control group (p = 0.7158) (Figure 2). 
Finally, overall survival during the first year following the fracture is displayed 
as a Kaplan-Meier estimate in Figure 3. Mortality rates for both groups are 
comparable at any time. At one year slightly more patients of the intervention 
group (93.07%, 95% CI = 88.33-95.93) were alive compared to the control 
group (91.51%, 95% CI = 87.24-94.40), however this difference is not 
significant (p = 0.4474). 
  
Chapter II: Traumatologic-geriatric post-fracture program 
59 
  
    CONTROL INTERVENTION P-VALUE 
  GROUP GROUP  
  (N = 253) (N = 193)  
 General complications*, n (%)     0.008 
  Yes 87 (34.39%) 91 (47.15%)  
  No 166 (65.61%) 102 (52.85%)  
 Local complications**, n (%)     0.307 
  Yes 27 (10.67%) 27 (13.99%)  
  No 226 (89.33%) 166 (86.01%)  
 Reinterventions, n (%)     0.044 
  Yes 10 (3.95%) 17 (8.81%)  
  No 243 (96.05%) 176 (91.19%)  
 
Table 3: Complications and reinterventions 
    (* most frequently: cardiac failure, respiratory failure, urinary tract infection) 
    (**most frequently: wound infection, haematoma, periprosthetic      
    fracture) 
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Figure 1: Time free from new fracture (all patients) 
 
 
 
 
Figure 2: Time free from new fracture (only patients without preceding fracture) 
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Figure 3: Overall survival 
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5. Discussion 
5.1. Development, characteristics and added value of the clinical pathway 
It was the aim of the actual study to develop a clinical pathway for secondary fracture 
prevention of fragility hip fracture patients. To call the intervention a clinical pathway, 
the following three requirements need to be fulfilled. At first, the intervention should 
be based on multidisciplinarity. Secondly, the content needs to be evidence based. 
Finally, the intervention should have an active follow-up.11 The actual intervention is 
based on multidisciplinarity by its development and implementation by the 
collaboration of the Department of Traumatology and the CMBD with the presence of 
a geriatrician, endocrinologist and rheumatologist. Furthermore, paramedical co-
workers of different services are involved in the implementation of the program 
(pharmacists, nurses, secretaries,...). 
The content of the program is evidence based: randomized controlled trials advocate 
the administration of anti-resorptive therapy for the prevention of secondary fragility 
fractures with the concomitant administration of calcium and vitamin D.14,21-23 The 
Belgian guidelines and reimbursement protocols are based on this evidence.16 
Finally, by the execution of the actual comparative study, the active recording and 
follow-up of the compliance to the program is clear and implicates the presence of 
the third requirement to call our intervention a clinical pathway. 
In addition to the multidisciplinarity, our clinical pathway tries to be surgeon driven as 
more recent studies indicate the possible positive role of the surgeon on secondary 
fracture prevention.24,25 
Finally, as it is clear that the economic consequences of fragility hip fracture 
treatment will only increase, the model of Miura26 ("Hip Fracture Service": an 
interdisciplinary program to improve the care for frail elderly people with acute hip 
fracture using existing hospital resources) was used and our pathway was initiated by 
the use of the existing personnel and facilities, leading to a minimum of extra costs. 
The decision to limit inclusion to patients, who are able to come to the CMBD on an 
ambulatory base, was based on the potential drawbacks of the pathway. So it was 
decided by the surgeon to consider the advantages of medical osteoporosis 
prevention, fall risk assessment and fall prevention measurements against the 
possible drawbacks, namely the effort to bring a bed-ridden and often not 
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communicating patient to the hospital. Mostly, this decision was taken after 
consultation of the family and the general practitioner. 
 
5.2. Comparability of study groups 
The intervention and the control group are comparable concerning mean age, gender 
differentiation, ASA-classification, fracture type, fracture treatment and time of follow-
up. There only is a significant difference between the study groups concerning 
preceding fragility fractures: there are significantly more preceding fractures in the 
intervention group (table 1). As a prior fracture results in a 2-fold increased risk for a 
subsequent fracture,1,10,27,28 we do not have an explanation for this difference.  
Despite the fact that all other characteristics of the study groups are comparable, the 
retrospective study design with the use of a historical control group could be prone to 
bias. Underreporting of previous fractures in the medical charts of the historical 
control group could also lead to this difference. 
 
5.3. Process parameters 
All of the three process parameters measured are significantly different between the 
study groups in favour of the intervention group (Table 2). Some authors strongly 
advise to optimize the treatment of the underlying osteoporosis at the moment of a 
fragility hip fracture by multidimensional interventions. In this context, we were able to 
make a difference by influencing three important process parameters with the 
implementation of our clinical pathway. 
First, 90% of the patients of the intervention group were treated with calcium and 
vitamin D after the surgical treatment of their fragility hip fracture. This was evaluated 
by the presence of calcium and vitamin D in the medication list during hospitalization 
and on discharge. As described in literature, this information doesn't tell anything 
about compliance and long-term compliance is often poor.19 The intake of calcium 
and vitamin D is a prerequisite for receiving antiresorptive therapy and in 
consequence (non)-compliance influences the effectiveness to prevent secondary 
fractures.  
Secondly, the referral to the CMBD is significantly higher in the intervention group 
compared to the control group with nearly 93% of the patients receiving an 
appointment at discharge of the hospitalization for their hip fracture. Nevertheless, 
only 70.55% of these patients do show up at the CMBD compared to 100% of the 
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patients of the control group (p < 0.001). This low number can be explained by the 
systematic referral of the patients of the intervention group. The patients of the 
control group are only referred to the CMBD on their personal request, so their 
intrinsic motivation and compliance as well might be higher. Informing the patients 
and their representatives about osteoporosis management by an osteoporosis case 
manager could even improve information transfer and compliance with follow-up 
procedures. 29 
Furthermore, equal numbers of patients from the control and intervention group 
undergo DEXA-scanning when coming to the CMBD (19.92% of the patients in the 
control group compared to 18.75% of the patients in the intervention group, p = 
0.809). This low number of DEXA-scans can be explained by the fact that a fragility 
hip fracture in itself is defined as a symptom of osteoporosis and leads to 
reimbursement of antiresorptive therapy in the Belgian health care system.7,16 DEXA-
scanning is only performed to define reference values for the follow-up of long-term 
treatment. 
Finally, we were not able to include information about fall risk assessment and fall 
preventive measurements in our study as the registration of these data was not 
performed in a standardized way. As the prevention of falls is part of the 
postoperative osteoporosis management as well7,17, this is an important point for 
improvement. 
 
5.4. Outcome parameters 
The intervention group suffered from a significantly higher number of general 
complications compared to the control group. This is probably due to a better 
reporting in the intervention group as a non-intended consequence of the 
implementation of our clinical pathway. There were also significantly more 
reinterventions in the intervention group although the number of local complications 
was only slightly and not significantly higher than in the control group (Table 3). This 
can possible be explained by a general change in the care for fragility hip fracture 
patients. Together with the implementation of the care pathway, more attention was 
given to local postoperative complications. The threshold to drain a postoperative 
haematoma or debride a wound because of suspected infection, was much lower 
than in the years before. 
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Our clinical pathway did not have a protective effect on the occurrence of recurrent 
fractures (Figure 1), even not in the subgroup of patients without a preceding fracture 
(Figure 2). The pathway had no effect on the 1-year mortality (Figure 3). At first sight, 
it could be disappointing that we were not able to show a strong effect with our 
intervention. Based on the Kaplan-Meier curve, we observed a 1-year refracture rate 
of 7% in the control group. Given this relatively low event rate, large samples sizes 
are needed to detect clinical relevant improvements. For example, with the current 
number of included subjects (N=446) there was 60.6% power to detect a halving of 
the refracture rate in the intervention group (i. e. 3.5%). This is based on a two-sided 
log-rank test with alpha=5%, assuming all patients having a follow-up of 12 months, 
an equal number of patients in both groups and an exponential distribution of the 
event times. The actual power of the study even turns out to be a bit lower, since not 
all patients have complete follow-up and since there is an imbalance in the number of 
patients (57% in control group, 43% in the intervention group). Even to detect a 
stronger effect of the intervention (2% versus 7% refracture rate) the study is slightly 
underpowered, i.e. the power equals 72%. 
Furthermore, it is striking that the mortality rate in general for the study and the 
control group is much lower than the expected mortality rate for fragility hip fracture 
patients with numbers reported as high as 20 to 30%.6,7,12,30 This finding might be 
explained by the fact that there is a strong patient selection by the exclusion of non-
ambulatory patients. In this way, probably the patients with the most comorbidities, 
functional impairment, frailty, and limited life expectancy were excluded. This 
selection bias however was implemented on an arbitrary base as explained before. 
Finally it has been shown extensively that it is very difficult to include long-term 
mortality in studies on geriatric hip fracture treatment. In our own systematic review 
of the literature and meta-analysis (Chapter I) we could only show a significant 
difference in long-term mortality for the non-randomized studies. As stated by other 
authors as well, this might be due to the heterogeneity of the included studies with a 
big variation in the content or the interventions of the studied clinical pathway.31 
Furthermore, mortality might not be the best outcome parameter to evaluate in this 
patient population as it might be influenced by a lot of other causes as well.8 A study 
on which set of outcome parameters to be used for this frail patient population also 
included parameters evaluating functionality (mobility, activities of daily living) 
besides other parameters like complications and re-admissions.32 
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5.5. Limitations of the study and outlook 
The limitations of the actual study can be summarized as follows. 
First, it is a retrospective study with a historical control group conducted by review of 
the patients' charts. This might explain that there are a lot of missing data: we don't 
have information of patients being treated for a complication or recurrent fracture in 
another hospital nor of patients with an uneventful postoperative evolution who were 
lost for follow-up. 
Secondly, the intended follow-up time in our study was one year with a realized mean 
follow-up time of 10 months in both the control and intervention group (Table 1). 
Moreover, the time to referral to the CMBD was 77 days in the intervention group and 
95 days in the control group. Together with a mean follow-up time of 10 months, the 
follow-up time after the administration of antiresorptive therapy was only 7 months. In 
the large-scale studies on antiresorptive therapy14,33, the relative risk reduction of 
recurrent hip fractures started at 12 months and progressively increased until the end 
of follow-up at 36 months. So prospective large-scale (multicenter) studies with a 
longer follow-up time will be definitely needed to solve this issue. In the actual 
context of limited health resources, the findings of these kinds of studies will be of 
utmost importance to balance the costs of pharmacological osteoporosis treatment 
against the efforts needed to increase patient compliance. In the meantime, it should 
be good to consider non-pharmacological refracture preventive measurements as 
well. Literature shows evidence for dietary measures (calcium and vitamin D 
suppletion) but the effectiveness of fall prevention strategies on the incidence of 
recurrent fractures is less clear7,34,35, so in this area as well further research is 
needed. For our study more specifically, efforts need to be made to integrate a fall 
evaluation program and measures for fall prevention in the program and to document 
these data in the patients' charts. Finally, the information transfer on the prevention 
of recurrent osteoporotic fractures to the patient, his relatives and their general 
practitioner should be adjusted. An introduction of an osteoporotic case manager in 
the traumatology department and providing patient information leaflets on hospital 
entry with a hip fracture, are the next steps to adjust our traumatologic-geriatric 
postoperative program for hip fracture patients. 
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6. Conclusion 
In this retrospective study, a traumatologic-geriatric post-fracture program for the 
prevention of osteoporotic recurrent fractures in geriatric hip fracture patients was not 
associated with a significant reduction in the number of recurrent fractures nor with a 
mortality reduction within the first year after the fracture. Nevertheless, a significant 
difference was observed between the two study groups for all process indicators. 
Options for further improvements of this program to optimize postoperative care for 
hip fracture patients need to be investigated. There is no doubt that the actual clinical 
pathway induced an awareness in co-workers for the problem of osteoporotic 
recurrent fractures and for interdisciplinary management of these complex patients. 
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1. Abstract  
Background: Helically shaped cephalic implants have proven their benefit to provide 
an improved stabilization of unstable hip fractures. However, cut-out ratios up to 
3.6% still occur. This in vitro study evaluated the biomechanical performance of a 
novel cement augmentation technique of the Proximal Femoral Nail Antirotation in 
surrogate femora. 
 
Methods: Four study groups were formed out of 24 polyurethane foam specimens 
with low density. Proximal Femoral Nail Antirotation blades were implanted, either 
non-augmented, or augmented using 3 milliliters of injectable 
Polymethylmethacrylate bone-cement. The influence of implant malpositioning was 
investigated by placing the blade either centered in the femoral head or off-centric in 
an anteroposterior direction. All specimens underwent cyclic loading under 
physiological conditions. Starting at 1000 Newton, the load was monotonically 
increased by 0.1 Newton/cycle until construct failure. Movement of the head was 
identified by means of optical motion tracking. Non-parametric test statistics were 
carried out on the cycles to failure, to compare between study groups. 
 
Findings: Compared to control samples; augmented samples showed a significantly 
increased number of cycles to failure (P = 0.012). In the groups with centric position 
of the Proximal Femoral Nail Antirotation blade, cement augmentation led to an 
increase in loading cycles of 225%. In the groups with off-centric positioning of the 
blade, this difference was even more accentuated (933%). 
 
Interpretation: Cement augmentation of the Proximal Femoral Nail Antirotation 
blade with small amounts of bone-cement for treatment of osteoporotic hip fractures 
clearly enhances fixation stability and carries high potential for clinical application. 
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2. Introduction 
Among fragility fractures, hip fractures constitute the most dramatic complication of 
osteoporosis and a major public health concern. From a clinical perspective, the 
major concern is the associated morbidity and mortality. Up to 25% of fragility-related 
hip fracture patients die in the year following their fracture and of those who do 
survive, again some 20% will have to be institutionalised because of the fracture and 
its clinical consequences.1-5 Because of the aging of the population, the incidence 
and costs related to hip fractures will continue to increase exponentially. By 2025, 
there will be an estimated more than three million of annual incident fractures in the 
United States, creating direct medical costs of $ 25 billion.6 Despite new 
developments in the management of age-related osteoporosis, a lack of awareness 
continues to contribute to underdiagnosis and undertreatment of the disease.7 In 
addition to surgeon-dependent factors like quality of reduction and correct positioning 
of the implant, bone quality plays a major role in the occurrence of fixation failure.8-10 
Especially cut-out, a failure mechanism characterized by migration of the implant 
through the cancellous bone of the femoral head, is significantly related to the bone 
mineral density of the proximal femur.11,12 Cut-out ratios up to 12.6% are reported in 
literature when using screw-based fixation types like the Dynamic Hip Screw (DHS), 
Gammanail or Proximal Femoral Nail (PFN) for the treatment of unstable 
intertrochanteric fractures.13-18 Helical and spiral blade concepts have been proven to 
biomechanically improve resistance to cut-out.19,20 However, cut-out ratios of the 
Proximal Femoral Nail Antirotation (PFNA) of up to 3.6% are still seen in 
clinics.18,21,22 The application of bone-cement based on for example, 
polymethylmethacrylate (PMMA) could potentially further reduce the risk of cut-out in 
severe osteoporotic cases. Biomechanically, a clear benefit of cement augmentation 
has already been demonstrated as exemplified by dynamic hip screw 
instrumentations placing the implant into an afore-injected cement volume.23,24 
Improved resistance to cut-out is believed to relate mainly to an increase in implant 
surface with reduced stress on the trabecular structure. Clinically, the first attempts of 
implant augmentation with promising outcome were reported back in 1985.25 
Surprisingly however, the technique never became clinical routine. This is most 
probably because of the concerns in the medical community regarding interference 
with fracture healing due to excessive cement application and the presence of 
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cement at the fracture site, the possible damage to periosteal blood supply leading to 
femoral head necrosis, leakage of PMMA into the hip joint and the difficulties 
regarding implant removal.24-28 Some of these objections however have already been 
disproven:  nonunion can be avoided by keeping the cement to the proximal fragment 
and out of the fracture site.25 Furthermore newly designed implants which allow for 
augmentation through the implant, will prevent cement leakage into the hip joint or 
into the fracture area.24,26 Finally, thermal necrosis can be avoided by the use of 
limited amounts of PMMA (not more than 3ml).29 By changing the properties of the 
PMMA and making it more viscous, the risk of cement leakage can even be further 
minimized.30 
In the current study, perforated PFNA-blades were augmented with 3 ml of an 
injectable medium to high viscosity PMMA cement. The cannulation of the implant 
and additional perforations allow for injection of the cement into the surrounding bone 
tissue subsequent to implant insertion. Hence, a decision in favour or against cement 
augmentation can be taken intra-operatively after the implant has been placed. The 
aim of our study was to biomechanically compare cut-out resistance and rotational 
stability under cyclic loading of PMMA augmented PFNA-blades with non-augmented 
instrumentation in surrogate femoral heads. In order to be able to provoke failures, a 
suboptimal implant positioning was chosen and this in two ways. First of all, in the 
study groups with center-center blade position, a tip-apex distance of 24 mm was 
chosen as the blade was inserted to a depth of 38 mm. In the study groups with an 
off-centric blade positioning of 7 mm to the antero-posterior direction, this resulted in 
a tip-apex distance of 25.89 mm. According to the literature, this rather large tip-apex 
distances would make the specimen more prone to cut-out.9 Secondly, an off center 
position of the helical blade would create a moment arm, making the construct 
rotationally unstable. 
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3. Materials and methods  
3.1. Specimens and instrumentation 
A total of 24 surrogate specimens with defined geometry were manufactured of 
cellular polyurethane foam (10pcf, 1522-10, Pacific Research Inc., Malmö, Sweden). 
This closed cell foam represents a standardized and uniform material with properties 
in the range of human cancellous bone. A density of 10 pcf (pounds per cubic foot, 
160.2 kg/m³) was chosen to mimic an osteopenic bone structure.31 Four study-groups 
(augmented / non-augmented with centered or off-centered implant position) were 
formed, each comprising of 6 samples (Table. 1). 
 
Group Treatment Implant position 
 1 Non-augmented Center 
 2 Augmented Center 
 3 Non-augmented Off-center 
 4 Augmented Off-center 
 
Table 1: Study design in terms of study groups 
 
The foam specimens (length 50 mm, width 38 mm, height 50 mm, Fig. 1a) were 
confined to a custom-made polymer shell (diameter 56 mm) mimicking the cortex of 
the femoral head for subsequent load introduction. With the aid of a special jig, a 3.5-
mm guide-wire was inserted into the foam either centered (groups 1 and 2) or with a 
7 mm antero-posterior offset (groups 3 and 4) generating a moment towards negative 
pitch of the blade under physiological loading conditions (Fig.1b). Standard PFNA-
blades (length 100 mm, Synthes GmbH, Bettlach, Switzerland) were inserted over 
the guide-wire without predrilling to a depth of 38 mm, yielding a 12 mm distance 
between the implant tip and the apex of the foam (Fig. 1c). For the augmented 
groups 2 and 4 modified PFNA-blades (length 100 mm, Synthes GmbH, Bettlach, 
Switzerland) with 12 lateral perforations were used (Fig. 2). To inject the bone-
cement, the guide-wire was removed and a side opening cannula (Vertebroplasty 
Needle Kit, 8 Ga, Article number: 03.702.216S, Synthes GmbH, Oberdorf, 
Switzerland, Fig. 2) was inserted into the cannulation of the implant to the full depth. 
The side opening at the tip of the cannula was enlarged to a dimension of 3 x 12 mm. 
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Injection of 3 ml PMMA bone-cement (Vertecem V+, Synthes GmbH, Oberdorf, 
Switzerland) was done in a standardized manner: after mixing of the components, 
the cement was filled into 3.0 and 1.0 ml syringes (Viscosafe Injection Kit, Article 
number: 07.702.210, Synthes GmbH, Oberdorf, Switzerland).32  First of all, the 
cannula was prefilled with 3.0 ml of PMMA. Subsequently, 1.0 ml of PMMA was 
injected through the perforations of the blade into the foam towards cranial. After 
turning the cannula by 180°, another 1.0 ml was injected. Finally, the cannula was 
withdrawn by 10 mm and the procedure was repeated injecting 0.5 ml cement 
towards cranial and 0.5 ml towards caudal. 
 
     
 
Figure 1: Foam specimen and instrumentation 
1a: Foam specimen. 
1b: Foam specimen confined to polymer shell with custom-made jig on top for guide-
wire placement either in the centre of the femoral head or at 7 mm anteroposterior 
offset. 
1c: Insertion of the PFNA-blade to a standardised depth. 
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Figure 2: Modified PFNA-blade with 12 lateral perforations for cement injection. A 
side-opening cannula was used for controlled cement application. The cannula was 
first inserted into the implant cannulation to the full depth to inject 2 ml of bone 
cement and then withdrawn by 10 mm to inject another 1 ml. 
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3.2. Mechanical testing 
Mechanical testing was conducted according to the model described by Sommers et 
al. simulating an unstable intertrochanteric fracture with lack of postero-medial 
support and load sharing at the fracture gap.33 Implant shafts were rigidly mounted to 
a base fixture at 149º to the horizontal plane. This setting reflected a 130º femoral 
neck angle, a 16º resultant joint load vector to the vertical plus 3º offset of the femoral 
shaft axis from the sagittal plane (Fig. 3a and 3b). The femoral surrogates were 
confined in a plastic shell to simulate the characteristics of a reduced unstable 
intertrochanteric fracture. A polymer back plate rested on two cylindrical rollers 
allowing the head to collapse into varus. The implant was free to slide mimicking full 
implant dynamic. Testing was performed on an MTS Mini Bionix II 858 hydraulic test 
system (MTS Systems Corp., Eden Prairie, USA) equipped with a 4 kN load cell. In 
order to simulate an alternating load during walking, a loading trajectory measured in 
vivo in the human hip was transferred to the femoral head. The curve was provided 
by Bergmann et al.34 Starting at 1000 N the load was monotonically increased by 0.1 
N/cycle until failure of the construct according to the protocol of Windolf et al.19 The 
load-valley was maintained at 100 N throughout the test. Cyclic testing was 
performed at 2 Hz. Testing was stopped when the crosshead displacement exceeded 
7 mm. 
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Figure 3a: Illustration of the simulated force introduction at the proximal femur 
according to Sommers et al, 2004: an assumed tilting of the femoral shaft of 3°, a 
130° CCD angle of the implant plus a 16° offset of the resultant hip joint contact force 
to the vertical results in a 149° angle between implant axis and direction of the force. 
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Figure 3b: Test set-up: the sample is free to rotate about the implant axis and could 
collapse into varus. An x-y table compensates the resulting displacements. A set of 
retro-reflective markers allows for detection of the head motion in six degrees of 
freedom. A second set of markers was attached to the shaft of the implant (not visible 
here) to measure migration of the implant. A physiological loading trajectory is 
transferred to the head in physiological orientation and is cyclically increased until 
failure of the construct (arrow “F”). The 149° angle between the implant axis and the 
direction of the force is also shown. 
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3.3. Data acquisition and evaluation 
Using an optical 3D motion tracking system with five ProReflex MCU digital cameras 
(Qualisys AB, Gothenburg, Sweden) the motion of the surrogate femoral head in 
terms of varus rotation and rotation around the implant axis was evaluated 
throughout the experiment. A reflective marker set was attached to the plastic shell 
(Fig. 3b). Additionally, a set of markers was attached to the shaft of the PFNA-blade 
in order to measure implant migration. For statistical analysis, failure criterions were 
set to 5° varus collapse and 10° rotation about the blade axis (Fig. 3c and 3d). Blade 
migration was defined as displacement of the implant tip greater than 1 mm. Number 
of cycles until failure at unloading condition (plastic deformation) was determined for 
each failure criterion. After checking the data for normal distribution (Shapiro-Wilk 
test), non-parametric test statistics were carried out. Multiple Mann-Whitney-U tests 
were performed on the cycles until failure for pairwise comparisons between study-
groups. P-values were corrected according to Bonferroni. Significance level was set 
to α = 0.05. 
            
     Figure 3c: Varus collapse, the movement is indicated by the arrow. 
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    Figure 3d: Rotation around the blade axis, the movement is indicated by the 
            arrow. 
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4. Results 
Compared to control samples, augmented samples showed an increased number of 
cycles to failure. The samples of the non-augmented groups 1 and 3 failed by cut-out 
of the implant, resulting in a varus collapse of the femoral head. In the presence of 
augmentation, the cement was split into a cranial and a caudal segment (Fig. 4). No 
severe damage of the implants was observed during the tests. For centric position of 
the PFNA-blade, the number of cycles to 5° varus rotation of the head was mean 
8,317 (SD  1,205) for the non-augmented group (1) compared to mean 27,025 (SD 
3,077) for the augmented group (2). This reflects a 225% increase in load cycles due 
to augmentation. This difference was even more pronounced in the study-groups with 
eccentric implant position (933% increase). Cycles to 5° varus collapse of the head 
were mean 1,992 (SD 1,771) for the non-augmented specimens (group 3) compared 
to mean 20,575 (SD 1,548) cycles when augmentation was performed (group 4). All 
pairwise comparisons between study-groups regarding varus rotation revealed 
statistically significant differences (all P = 0.012). Figure 5 shows the varus rotation of 
all groups in the course of testing. In contrast to the specimens with centric blade 
position, all specimens of the groups with off-centric blade placement (groups 3 and 
4) revealed additional head rotation around the blade axis. Number of cycles to 10° 
head rotation was mean 1,200 (SD 1,376) for the non-augmented off-center group 
(3) and mean 20,575 (SD 1,548) for the augmented off-centric specimens (group 4). 
This difference was significant between groups (P = 0.002) (Fig. 6). In the off-center 
group without augmentation (3), 3 out of 6 samples showed early failure due to 
backing out of the blade (migration > 1 mm). As soon as the test started, the blade 
tended to wander out of the surrogate towards distal with simultaneous rotation of the 
femoral head. 
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Figure 4: Radiographs of an instrumented specimen before (left) and after testing 
(right).  Left: A cement cloud surrounding the PFNA-blade increases the anchorage. 
Right: After intensive loading, the cement volume is split and the specimen shows 
typical varus collapse as clinically seen in the presence of cut-out. 
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Figure 5: Boxplots of the number of cycles until 5° varus collapse of the femoral head 
for all study groups. The augmented samples with centric implant position revealed 
the highest stability; the non-augmented, eccentric specimens failed earliest in the 
course of testing. All groups were statistically different with respect to each other (all 
P = 0.012). 
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Figure 6: Boxplots of the number of cycles until 10° rotation of the sample about the 
implant axis for the study groups with eccentric implant position. The centrically 
placed specimens did not exceed this failure criterion. A highly increased stability due 
to augmentation is obvious. 
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5. Discussion 
The problem of fixation failure of cephalic hip implants for the treatment of 
intertrochanteric fractures is well known. Causes can be divided into two major 
groups. First of all, there are a number of surgeon and surgical technique related 
issues, like insufficient reduction or suboptimal positioning of the implant.25,35 
Secondly, fixation failures are more likely to occur in osteoporotic bone.8 
New implant designs have improved failure rates but cut-outs remain an issue.21,22 
Because osteoporosis continues to be underdiagnosed and undertreated, surgical 
options are mandatory.12,36 Both in biomechanical and clinical studies, the technique 
of cement augmentation of cephalic implants to increase the anchorage in 
osteoporotic femoral heads has been successfully introduced.24-27,37,38  
This in-vitro study evaluated a novel PMMA augmentation concept of the helical 
blade of the Proximal Femoral Nail Antirotation (PFNA) in terms of cut-out resistance 
and rotational stability using surrogate femoral heads. The augmented implants with 
centered position showed an increase in the number of cycles to fatigue failure by 
225% when compared to non-augmented controls. In cases of eccentric implant 
placement, this difference was even more pronounced. In agreement with other 
studies, these results strongly suggest that augmentation enhances implant 
anchorage and carries potential to prevent fixation failure, even in cases with mal-
positioned hardware.24,25 However, in the first instance, augmentation is meant to 
compensate for reduced bone quality. 
Our study showed that off-centered positioning affects implant purchase even when 
associated with augmentation. Misinterpretation of the method as “all-purpose tool” 
against cut-out should be avoided in any case. Proper fracture reduction and 
accurate implant positioning remain key factors to achieve a satisfying surgical 
outcome. 
Before augmentation can be embedded into the existing surgical technique, some 
additional steps are needed. One strategy could be to use perforated implants. The 
same implant could then be used solely or combined with augmentation. The 
decision to augment can be taken during the surgical intervention on the basis of 
distinct criteria. The opportunity to inject bone-cement after placing the implant 
represents a clear advantage in terms of safety. Major complications, like missing the 
implant insertion during the curing period of the cement, can be excluded. No implant 
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failures were observed during the course of testing. A relatively viscous type of 
PMMA cement was used. It was technically feasible to inject the PMMA but a 
comparatively high injection pressure was required. 1 ml syringes provided a feasible 
transmission of the injection forces and allowed for controlled cement application. By 
using injectable medium-to-high viscosity PMMA, undesired cement leakage may be 
avoided.32 Cement portions could block the sliding capability of the implant or could 
squeeze into the fracture site. This might lead to healing complications like non-
unions, persistence of non-reducible fracture gaps and interference with periosteal 
healing.26,39 To minimize the risk for avascular- and heat-necrosis during PMMA 
polymerization, and, in more general terms, to follow the principle of minimal 
alteration of an existing biology, a limited amount of PMMA (3 ml) was used.28,29 
Excessive application of PMMA could destruct cartilage because of subchondral 
cement localization, or could generate fat emboli. In addition, excessive amounts of 
PMMA alter the risk of infection25 due to the potential space for bacteria adhesion 
and the possible tissue necrosis associated to heat generation. With respect to 
implant removal, no problems were encountered when withdrawing the blade from 
the cement volume. Removal of the blades was performed on each test specimen 
with the dedicated instrument and following the surgical technique as provided by the 
manufacturer. The extraction screwdriver was attached to the blade by turning it 
counter clockwise and gentle blows were applied with the hammer. As mentioned by 
other authors, the cement sheared completely off the implant.40 The relicts of bone-
cement could complicate revision surgeries but drillable PMMA, as used in this study, 
allows for anchoring implants in a hardened state. The use of alternative biomaterials 
like degradable Calcium-Phosphate cements might be an option for the future. 
However, the mechanics of current formulations, especially concerning shear27, are 
still not comparable to PMMA based solutions in load bearing applications. 
A polyurethane foam model with comparatively low density was used to imitate 
severely osteoporotic bone. The foam type was chosen from pilot experiments to 
achieve an acceptable compromise between loading regime, number of test-cycles 
until fatigue failure, and failure patterns. All parameters were in line with those in 
previous test trials using human cadaver bones in the same setting. However, the 
question to what extent our results can be extrapolated to clinical practice remains 
open.  
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The use of synthetic bone structures for biomechanical testing is still subject to 
ongoing debate et al.41,42 The foam we used showed closed porosity, which might 
alter cement distribution compared to an open trabecular structure. However, the 
derived cement volumes surrounding the implants appeared homogenous and were 
comparable to the infiltration observed in cadaver samples. In human bones, 
trabecular structure and bone density might vary along the blade axis, which could 
lead to a more scattered cement distribution. However, as shown in another study, 
our cement was optimized to enhance uniform filling.32 
Our test setup simulated the dynamic situation of a reduced, unstable 
intertrochanteric hip fracture after completion of implant sliding.33 A controlled load 
sharing between implant and fracture site was established. Since our focus was on 
the implant-bone interface, an isolated head model was deemed as most practical 
despite though general limitations. To avoid secondary failures, PFNA-nail and 
femoral shaft fragment were not considered, limiting the modelling of the actual 
biomechanical situation to an acceptable extent. The center of varus-rotation was 
statically located at the center of the roller, whereas the actual rotational center might 
dynamically migrate. The polymer shell confining the head samples does only 
marginally compare to the anatomical dimension of a femoral head which alters the 
acting lever arm between joint force vector and implant. However, the observed 
failure patterns like a varus collapse of the femoral head were comparable to the 
ones seen in clinic, supporting clinical relevance of our model. Cyclic testing was 
performed using an in-vivo measured loading curve simulating the main forces acting 
in the hip joint during gait.34 A 3D motion analysis system was used for data 
acquisition because spatial movement of the head fragment had to be assessed. 
Assuming test fixture and implant as rigid, a reference marker-set was not installed. 
Compliance of the system was therefore neglected. 
To interpret our findings with more confidence, follow-up investigations on fresh 
frozen cadaveric femoral heads should include assessment of bone mineral density. 
Ultimately, the full operational procedure should be evaluated in a clinical setting. 
Potential issues associated with cement injectability, cement leakage, implant 
removal and revision surgeries will require further assessment before bringing this 
promising technique into clinical practice. 
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6. Conclusion 
The technique of implant augmentation using bone-cement appears to significantly 
enhance the implant anchorage in a context of poor bone quality. Our promising in 
vitro results suggest that augmentation of the PFNA–blade with small amounts of 
PMMA cement in the treatment of osteoporotic hip fractures clearly enhances fixation 
stability and carries high potential for clinical application. 
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Chapter IV 
 
 
Potential of PMMA cement-augmented helical PFNA blades 
to improve implant stability – a biomechanical 
investigation in human cadaveric femoral heads 
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polymethylmethacrylate cement-augmented helical proximal femoral nail antirotation 
blades to improve implant stability - A biomechanical investigation in human 
cadaveric femoral heads. J Trauma 2012; 72: 54-59 
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1. Abstract 
Background: Cement augmentation may improve fixation stability and reduce cut-
out rate in the treatment of intertrochanteric hip fractures. The aim of this study was 
to compare the number of cycles to failure of polymethylmethacrylate-augmented 
helical blades with non-augmented ones in human cadaveric femoral heads. 
 
Methods: Six pairs of cadaveric femoral heads were instrumented with a perforated 
Proximal Femoral Nail Antirotation blade. Within each pair, one blade was 
augmented using 3 ml of polymethylmethacrylate. All specimens underwent cyclic 
axial loading under physiological conditions. Starting at 1000 N, the load was 
monotonically increased by 0.1 N/cycle until construct failure occurred. To monitor 
the migration of the blade, anteroposterior radiographs were taken at 250 cycle 
increments. Non-parametric test statistics were carried out to calculate correlations 
and identify differences between study groups. 
Results: Inducing failure required a significantly higher number of cycles in the 
augmented group (p = 0.028). Bone mineral density was significantly related with the 
number of cycles to failure in non-augmented specimens (p < 0.001, R2 = 0.97), but 
not in the augmented group (p = 0.91, R2 = 0.34). 
Conclusion: Implant augmentation with small amounts of polymethylmethacrylate 
enhances the cut-out resistance in proximal femoral fractures. Especially in 
osteoporotic bone, the procedure may improve patient care. 
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2. Introduction 
Recently developed intramedullary implants with new features are increasingly used 
in the treatment of intertrochanteric hip fractures.1,2 With the introduction of helical 
blade designs for improved anchorage in the femoral head, the incidence of cephalic 
implant cut-out has dropped from approximately 12% 3 to 3.6%.4 However, in the light 
of the known demographic pressure and the aging of the population, optimizing 
fracture fixation remains a priority. Particularly in osteoporotic bone, providing 
confident and reliable fracture treatment could lead to earlier load bearing and 
functional recovery with the potential to reduce morbidity and even mortality. The 
mechanical competence of osteosynthesis depends on a number of factors. In 
addition to surgery-related issues, such as insufficient reduction or suboptimal 
implant positioning5,6,7, bone quality would also appear to be critically important.8 In 
older individuals, bone quality tends to be compromised by osteoporosis, a systemic 
skeletal disease that continues to become more prevalent but also continues to be 
underestimated and undertreated.9 Cement augmentation of cephalic hip implants 
may enhance the implant anchorage, as shown in biomechanical studies.10,11 The 
Proximal Femoral Nail Antirotation (PFNA, Synthes GmbH, Bettlach, Switzerland) 
was adapted for additional bone cement application to improve mechanical 
competence. The PFNA blade is laterally perforated along its axis to enable 
controlled cement injection through the cannulation of the implant into the cancellous 
bone structure. Augmentation is performed using a new acrylic cement formulation 
with medium to high viscosity. The technique allows the surgeon to decide for or 
against cement augmentation after the implant has been inserted.  Until now, we are 
not able to perform an intra-operative quantitative assessment of the bone quality, 
but systems that will enable us to perform an intra-operative mechanical assessment 
of local bone strength are under development (DensiProbeTM AO Research Institute, 
Davos). 
The purpose of this in vitro study was to analyse the biomechanical potential of a 
newly proposed PFNA cement augmentation concept in osteoporotic human 
specimens. 
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3. Materials and methods 
Six pairs of fresh frozen (-20°C) human cadaveric proximal femurs with low bone 
density12 were used in this study, selected out of 15 pairs of femurs from female 
donors above the age of 80 according to bone mineral density (BMD). BMD was 
measured by peripheral quantitative computed tomography (pQCT) using an Xtreme-
CT (SCANCO Medical AG, Bassersdorf, Switzerland). A cylindrical area of 20 mm 
diameter and 30 mm length in the center of the femoral head was evaluated, 
corresponding to the target location of the helical blade and cement cloud. 
The six paired samples with the lowest BMD values were included in the study. One 
femur of each pair was randomly assigned to conventional helical blade fixation, 
while the contralateral one was treated with a cement-augmented helical blade. 
The instrumentation was performed pairwise by an experienced surgeon. Each femur 
was sawed 50 mm distal to the articular surface, in a plane orthogonal to the planned 
implant axis. To place a guide-wire in the centre of the femoral head, a custom-made 
jig was used (Figure 1). The guide-wire was inserted to a depth of 40 mm to avoid 
perforation of the femoral head. Perforated PFNA blades (PFNA Blade, perforated, 
length 100 mm, 04.027.035S, Synthes GmbH, Oberdorf, Switzerland; Fig. 2) were 
inserted over this K-wire without predrilling to a depth of 38 mm. Hence a 12 mm 
distance was left between the tip of the implant and the apex of the femur 
corresponding to a tip-apex distance of 24 mm according to the definition of 
Baumgaertner et al.5 Subsequently, the guide-wire was removed. In the augmented 
group, a side opening disposable cannula (Traumacem Needle Kit, Ø 3.3 mm 
cannula with side-opening, 03.702.120S, Synthes GmbH, Oberdorf, Switzerland; 
Figure 2) was filled with PMMA bone cement (Vertecem V+, LOT 09CA53010, 
Synthes GmbH, Oberdorf, Switzerland) with 3 ml syringes (Viscosafe Injection Kit, 
07.702.210, Synthes GmbH, Oberdorf, Switzerland) and inserted into the cannulation 
of the blade to the full depth. Augmentation of the implant with 3 ml of bone cement 
was performed in a standardized manner with the plunger provided with the cannula 
system (Traumacem Needle Kit, Ø 3.3 mm Cannula with side-opening, 03.702.120S, 
Synthes GmbH, Oberdorf, Switzerland); 1 and 0.5 ml etched markings on the plunger 
provided information on the amount of injected cement. After injection of 1 ml of 
PMMA through the perforations of the blade into the cranial side of the femoral head, 
the cannula was turned 180°, allowing caudally directed injection of another 1 ml. 
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Subsequently, the cannula was withdrawn over 10 mm and the same procedure was 
repeated by injecting 0.5 ml of PMMA twice. 
Mechanical testing was conducted according to the model described by Sommers et 
al.13 (Figure 3), simulating an unstable intertrochanteric fracture with a lack of 
postero-medial support and load sharing at the fracture gap. Implant blade shafts 
were rigidly mounted to a base fixture at 149º to the vertical plane. This setting 
reflects a 130º femoral neck angle, a 16º resultant joint load vector to the vertical, 
plus 3º offset of the femoral shaft axis from the sagittal plane. The femoral heads 
were mounted on a polymer back plate which rested on two cylindrical rollers, 
allowing for varus collapse of the head and simulating the characteristics of a 
reduced unstable intertrochanteric fracture. The blade was free to slide, mimicking 
full implant dynamic. 
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Figure 1 
Custom-made jig for guide-wire placement in the centre of the femoral head 
 
 
 
 
Figure 2 
Modified PFNA-blade with 12 lateral perforations for cement injection. A disposable 
side-opening cannula was used for controlled cement application. The cannula was 
first inserted into the implant cannulation to the full depth to inject 2 ml of bone 
cement and then withdrawn by 10 mm to inject another 1 ml. 
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Figure 3 
Setup for mechanical testing according to Sommers et al. The sample is free to 
rotate around the implant axis and can collapse into varus. An x-y table compensates 
the resulting displacements. A K-wire allows for detection of the head motion. A 
physiological loading trajectory is transferred to the head in physiological orientation 
and is cyclically increased until failure of the construct. 
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Testing was performed on a MTS Mini Bionix II 858 hydraulic test system (MTS 
Systems Corp., Eden Prairie, USA) equipped with a 4 kN load cell. In order to 
simulate an alternating load during walking, a loading trajectory resulting from in-vivo 
measurements in the human hip was transferred to the femoral head.14 Starting at 
1000 N the peak load was monotonically increased by 0.1 N/cycle, while the load-
valley of the trajectory was maintained at 100 N.15 Cyclic testing was performed at 2 
Hz and was stopped when the displacement of the machine actuator exceeded 10 
mm. This value provoked a distinct damage at the bone-implant interface in all cases 
allowing meaningful retrospective data evaluation. 
Data acquisition was performed by radiographic imaging using an image intensifier 
(Siemens Arcadic Varic, Siemens Medical Solutions AG, Munich, Germany). 
Anteroposterior radiographs were taken every 250 cycles at the minimum load, to 
monitor the movement of the head with respect to the blade. The position of the 
image intensifier was maintained constant throughout the experiment. The varus 
rotation of the femoral head with respect to the initial X-ray was determined from the 
radiographs by means of image processing algorithms (Matlab, Mathworks Inc., 
Natick, USA). A varus collapse of 2°, indicative for loosening of the helical blade, was 
defined as the point of failure. The number of test-cycles to failure was identified for 
all specimens. After assessing data distribution (Shapiro-Wilk test), paired non-
parametric test statistics (Wilcoxon signed ranks) were carried out to identify 
differences between groups regarding cycles to failure and BMD. Spearman’s 
correlation coefficient R2 was calculated for cycles to failure and BMD for both 
groups. The significance level was set α = 0.05. 
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4. Results 
Bone mineral density of the 6 bone pairs was 142 mgHA/cm³ on average, with a 
standard deviation (SD) of 35. No statistical difference (p = 0.35) was found for BMD 
between groups (non-augmented: 145 mgHA/cm³ (SD 42); augmented: 138 
mgHA/cm³ (SD 30)). 
The augmented specimens had to be subjected to a significantly higher number of 
cycles to induce failure (p = 0.028). The mean number of cycles to failure was 22,708 
(SD 4,411) for the augmented and 15,042 (SD 7,226) for the non-augmented group, 
respectively (Figure 4). All constructs failed by implant cut-out, resulting in a varus-
type collapse of the femoral head (Figure 5). No implant failures were observed 
during the tests. 
The relation between BMD and number of cycles to failure is shown in Figure 6 for 
both groups. A significant correlation was observed between BMD and the number of 
cycles to failure for non-augmented specimens (p < 0.001, R2 = 0.97). No correlation 
was found in the augmented group (p = 0.91, R2 = 0.34). A significant correlation was 
observed between BMD and the percentage increase in cycles to failure due to 
augmentation (p < 0.001, R2 = 0.99, non-parametric test). The impact of cement 
augmentation was inversely related with BMD (Figure 7). 
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Figure 4 
Boxplots of the number of cycles until 2° of varus rotation of the femoral head for 
both study groups. The augmented samples revealed the highest stability. 
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Figure 5 
Radiographs of an instrumented non-augmented specimen before (A) and after (B) 
testing and radiographs of an instrumented augmented specimen before (C) and 
after (D) testing. After intensive loading, the specimen shows typical varus collapse 
as clinically seen in the presence of cut-out in both the non-augmented and the 
augmented case. 
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Figure 6 
Diagram showing the relation between BMD and number of cycles to failure for both 
groups. A significant correlation was observed between BMD and the number of 
cycles to failure for non-augmented specimens (p < 0.001, R2 = 0.97). No correlation 
was found in the augmented group (p = 0.91, R2 = 0.34). 
 
 
 
 
 
 
Figure 7 
Diagram showing the correlation between BMD and difference in number of cycles to 
failure. A significant correlation was observed between BMD and the percentage 
increase in cycles to failure due to augmentation (p < 0.001, R2 = 0.99, non-
parametric test). The impact of cement augmentation was inversely related with 
BMD. 
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5. Discussion 
The aim of this study was to compare PMMA augmented helical blades to non-
augmented controls in human cadaveric femoral heads. A new augmentation-based 
implant-set and the corresponding procedure for PFNA were evaluated in a 
laboratory environment. The results confirmed that even with small amounts of bone 
cement (in every augmented specimen 3 ml of Polymethylmethacrylate was 
injected), augmentation significantly improves the implant anchorage in bone of low 
quality. 
In the context of the loading protocol, the constructs, on average, sustained 51% 
more load-cycles when cement augmentation had been performed. In augmented 
specimens, no correlation was observed between BMD and cycles to failure, 
supporting the concept that augmentation rules out the impact of low bone quality 
and hence reduces the impact of osteoporosis on the implant purchase. On the other 
hand, the effect of augmentation is reduced with increasing bone quality, suggesting 
that PMMA augmentation is primarily useful in osteoporotic bone. 
Translating the high resolution pQCT measurements to a clinical context needs to be 
performed with caution, since DEXA (dual energy X-ray absorptiometry) is the 
predominant method to diagnose osteoporosis. The fact that we used samples from 
women over the age of 80 – the segment of the population most at risk of 
osteoporotic fractures – further adds to the clinical relevance of our findings. Other 
authors12 measured a representative population of 174 cadaveric femora (median 
donor age 87) with CT and reported bone mineral densities corresponding to 
approximately 90 – 290 mgHA/cm³. Hence, our data ranging between 98 – 220 
mgHA/cm³ suggests that our samples were representative of the overall elderly 
population. 
Support for potential clinical benefits of implant augmentation comes from both 
biomechanical and clinical studies. A significant increase in the initial fixation stability 
of a modified and augmented hip screw compared to a conventional one, has been 
demonstrated in an intertrochantric fracture model. In agreement with our findings, 
the most improvement in the context of the lowest bone quality was reported.10 
Another biomechanical study provided evidence for the benefit of hip screw 
augmentation under cyclic loading, with significantly smaller head displacements and 
lower failure rates in augmented specimens.11 In a clinical study, a significantly lower 
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complication rate in intertrochantric fracture patients treated with cement 
augmentation, was reported.16 
Despite supportive evidence, implant augmentation has not achieved a clinical 
breakthrough yet. Reasons for the rather restrained acceptance of the concept in the 
medical community may be manifold. One explanation is that, up to now, a 
standardized technique and a dedicated implant set were missing. In this paper, we 
present a procedure for PFNA which allows controlled injection of bone cement. 
Standard instrumentation can be performed with the known biomechanical 
advantages of blade implants.17 The lateral perforations of the modified blade implant 
represent a potential weak point of the implant. Standardized material testing of the 
implants, as performed by the manufacturer in beforehand, revealed no increased 
risk for implant failure due to the perforations. Furthermore our tests did not reflect 
any failure of the implant itself. If required, the anchorage may be further enhanced 
by additional cement augmentation. In our study, this was done according to a 
defined protocol. Compared to previously reported augmentation techniques, 
possible devastating complications can be avoided by including careful adaptations 
to this protocol, of which avoidance of femoral head perforation, the use of a limited 
amount of PMMA and localization of the PMMA around the implant are the most 
important. 
In the current clinical workflow, feedback during surgery is essentially based on 
subjective judgment by the surgeon. Most hip fracture patients do not undergo DEXA 
or CT measurement. However, to prevent unnecessary cement injection, a 
quantitative assessment of the bone quality might be useful, since cement 
augmentation seems to be most effective in osteoporotic bone. Mechanical 
assessment of local bone strength might be an alternative. In fact, in a number of 
biomechanical experiments, measuring the breakaway torque of the local trabecular 
structure (DensiProbeTM AO Research Institute, Davos) during surgery has been 
proven to reliably predict implant cut-out at different anatomical regions.18 Application 
of this concept to the hip is currently investigated in a clinical multicenter trial and 
may ultimately be included in the PFNA implantation-set as a next step. 
When using cement injection, extravasation of non-biodegradable bone cement into 
the hip joint might have devastating consequences. A perforation of the K-wire 
through the femoral head should therefore be avoided. In cadaver experiments and  
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in in vivo trials, preserved cortical and cartilage layers were verified by injection of 
Iopramida contrast agent (Ultravist 300, Schering AG, Zürich, Switzerland) prior to 
cement application. When leakage of the contrast agent is identified by radiography, 
augmentation should be strictly avoided. One strategy to reduce the risk of cement 
leakage, is to use a new type of PMMA cement with a medium to high viscosity19. In 
our cadaver experiments, it seemed that the required injection pressure increased 
with increasing BMD. In fact, in some of our pilot specimens with higher bone density 
values, it was not even possible to manually inject cement into the bone structure. In 
some experiments, we recognized a scattered, uneven distribution of the PMMA 
along the blade axis in spite of a standardized augmentation technique (Fig. 5), with 
PMMA accumulating at the tip or at the base of the helical blade or at the cranial or 
caudal site, respectively. In addition to inhomogeneities of the bone structure, 
cancellous bone compaction as a result of implant insertion15 might impede or 
redirect the cement flow towards a certain region. However, the relevance of these 
issues from a clinical perspective remains to be clarified. Nevertheless, from a 
biomechanical perspective, it would seem that the cement should be concentrated at 
the implant tip and that radiographic monitoring of cement distribution is 
recommended. Baumgaertner et al.5 already expressed the importance of the tip-
apex distance as key-factor for a successful component outcome. Mechanically, 
reducing the distance between implant tip and apex reduces the lever-arm of the hip 
joint contact force and hence diminishes the stresses in the bone structure. 
Accentuated presence of bone cement at the tip might therefore be beneficial from a 
biomechanical perspective. The individual roles of several key factors, such as 
cement location, amount of cement, tip-apex distance, with regard to the implant 
anchorage is still unclear and will be the subject of future experiments. 
Potential drawbacks of PMMA augmentation such as cement leakage, fat emboli, 
toxicity, thermal effects and devascularisation are directly related to cement volume 
and distribution.20 Contrary to studies performed by pioneers in PMMA application for 
the treatment of unstable intertrochanteric hip fractures21, we used comparatively 
small amounts of bone cement (3 ml) to minimize impact on the biological 
environment. The risks of cement leakage and fat emboli have been evaluated in 
vertebroplasty related studies, where in an extreme case of multiple level 
augmentation total cement volumes of up to 25 ml have been advocated as safe22  
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but this should also be evaluated in the hip joint. In addition to cement volume, heat 
generation may have safety implications as well. One of the concerns with heat 
generation due to exothermic polymerization is osteocyte necrosis. According to a 
previously performed ex vivo study23, the used cement volume of 3 ml may not affect 
bone sensitivity to thermal destruction. Finally, it should be noted that chondrocytes 
might be more sensitive to the deleterious effects of PMMA than osteocytes. 
Therefore, any subchondral localization of bone cement should be avoided.24 The 
absence of temperature monitoring at the surface of the femoral head during the 
application of PMMA, can be considered as a first limitation of this study. Besides 
this, some other limitations need to be mentioned. First of all, only one mode of 
failure (varus collapse and cut-out of the helical blade) was tested, whereas other 
modes of failure like backing-out of the helical blade and non-sliding of the system 
have been mentioned in clinics. Secondly, only uni-axial loading was tested while 
multiplanar loading, more suggestive to normal gait, was not tested. In our 
experiments, a suboptimal implant position was chosen as represented by a rather 
large tip-apex distance (24 mm according to Baumgaertner et al.). This configuration 
created a worst-case scenario and provoked clinical failure even in specimens with 
healthy bone stock. However, clinically a reduced tip-apex distance is recommended. 
With regard to implant removal, our tests in the laboratory did not reveal any 
difficulties to withdraw the blade from the cement volume. A layer of fat and bone 
marrow between implant and cement might prevent bonding of the materials. In the 
unlikely event of a revision osteosynthesis, where arthroplasty would normally be the 
operation of choice, it was already suggested to power drill and tap PMMA cement. 
Some of the abovementioned risks and dangers are related to the nature of acrylic 
based biomaterials. Biodegradable bone cements, e.g. those based on calcium 
phosphates, are upcoming. Possible advantages are disintegration of leaked cement, 
the absence of an exothermal reaction and the feasibility of revision operations.25 
Nevertheless, inferior biomechanical properties disqualify currently available 
biodegradable alternatives for the indented use.11 Moreover, their disappearance 
over time due to resorption questions the application in old and frail patients in whom 
avoidance of fixation failure and refracturing are of utmost importance. 
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6. Conclusion 
This ex vivo study shows that implant augmentation with small amounts of bone 
cement significantly enhances the cut-out resistance in proximal femur fractures 
treated with a modified PFNA. The procedure is primarily indicated for osteoporotic 
bone and appears to be a valuable treatment option with clinical benefits in the 
elderly that seem to outweigh any possible risks associated with implant 
augmentation. 
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1. Abstract 
Purpose: Several studies have proven the beneficial effect of cement augmentation 
of Proximal Femoral Nail Antirotation (PFNA) blades on implant purchase in 
osteoporotic bone. It is the purpose of this in vitro study to investigate the effect of 
different localisations and amounts of bone cement. 
 
Methods: Polyurethane foam specimens were instrumented with a PFNA blade and 
subsequently augmented with polymethylmethacrylate (PMMA) bone cement. Eight 
study groups were formed based on localisation and amount of cement volume 
related to the blade. All specimens underwent cyclic loading with physiological 
orientation of the force vector until construct failure. Foam groups were compared 
between each other and to a cadaveric control group. 
 
Results: The experiments revealed a significant dependency of implant purchase on 
localisation and amount of cement used. Biomechanically favourable cement 
positions were found at the implant tip and at the cranial side. However, none of the 
tested augmentation patterns performed significantly inferior to the cadaveric 
benchmark. 
 
Conclusion: In an experimental test setting, localisation and amount of cement 
influenced the biomechanical competence of augmented PFNA blades in simulated 
porous cancellous bone. These findings will allow surgeons to further reduce the 
amount of injected PMMA, decreasing the risk of cement leakage or cartilage 
damage. 
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2. Introduction 
With the use of novel fixation devices like helical blades for the treatment of proximal 
femoral fractures, the incidence of cut-out of cephalic implants has decreased 
importantly.1-5 Nevertheless failures do occur. Besides surgeon related factors such 
as the quality of the reduction and the positioning of the implant, the bone quality 
plays an important role in the occurrence of devastating mechanical complications.6,7   
Due to the aging of our population and the relatively poor compliance to drugs that 
prevent osteoporotic fractures, the incidence of osteoporosis related fractures will 
increase.8 
The technique of implant augmentation is based on an increasing congruence 
between the implant and the bone thereby reducing the stresses developed at the 
implant to bone interface.9,10 A biomechanical study on augmentation of conventional 
hip screws showed beneficial results in osteoporotic cadaveric bones.11 
Subsequently, implant augmentation was performed through a cannulated and 
perforated implant. In several in vitro studies, cement augmentation of Proximal 
Femoral Nail Antirotational blades (PFNA, Synthes GmbH, Bettlach, Switzerland) has 
been proven to be clearly beneficial in terms of biomechanical performance in 
osteoporotic bone.12-14 Recently, the first clinical results of PFNA helical blade 
augmentation were published.15 
However, both in vitro and in vivo studies revealed a considerable variation of 
cement distribution around the implant when using at least 3 ml PMMA. Accurate 
positioning of the cement seems difficult to achieve. The exact role of localisation and 
cement volume on the implant purchase is unclear. Determination of an optimal 
localisation and volume for the cement could reduce the risk of several hazards 
accompanying cement application, such as cement leakage or adverse effects on the 
cartilage.16 
The objective of this experimental study was to systematically investigate the effect 
of localisation and amount of PMMA cement on the mechanical competence of PFNA 
proximal femur constructs under cyclic loading. We wanted to determine the position 
and the amount of bone cement needed to achieve sufficient implant purchase in the 
osteoporotic femoral head with minimal alteration of the biological system. 
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3. Methods 
3.1. Study-groups 
36 surrogate foam specimens with defined geometry were used as model for human 
cancellous bone (Figure 1). The specimens consist of cellular polyurethane foam (10 
pcf, 1522-10, Pacific Research Inc., Malmö, Sweden) representing human cancellous 
bone. We used a density of 10 pcf (pounds per cubic foot, 160.2 kg/m³) to simulate 
an osteopenic bone structure.13,17 These samples were divided into six study groups 
(n = 6) with different amounts and localisations of cement with respect to the blade 
(groups 1-6, Figure 2, Table 1). From a previous study with similar settings, the 
mechanical test raw data from a group with concentric distribution of 3 ml PMMA at 
the tip of the blade (n = 6) and a non-augmented control group (n = 6) were re-
evaluated to fit the failure criterion of the present study of 2° of varus collapse and 
integrated in the present study (groups 7-8).13 Additionally, two reference groups 
were established from 12 fresh-frozen human cadaveric femoral heads. These 
reference groups were accomplished by adding the re-evaluated mechanical test raw 
data of the 6 non-augmented cadaveric femoral heads of a former study14 to the 
mechanical test raw data of 6 cadaveric femoral heads instrumented with a helical 
blade without augmentation for the present study. The cadaveric femoral heads 
consisted of 4 right and 8 left bones, 8 females and 4 unknown at a mean age of 87.2 
± 5.2 years (mean ± SD) with a range between 81 and 96 years. Specimens were 
obtained from the Department of Pathology, Kantonspital Basel, Switzerland, with 
appropriate consent of the relatives. 
Prior to testing, all human specimens underwent bone mineral density (BMD) 
measurements in the cancellous bone with peripheral quantitative computed 
tomography (pQCT) using an Xtreme-CT (SCANCO Medical AG, Bassersdorf, 
Switzerland). According to the mechanical testing results, the specimens were 
retrospectively divided into "weak" and "strong" cadaveric groups (groups 9-10, n = 6, 
see Data acquisition and evaluation). 
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Figure 1: Foam specimen 
Polyurethane foam block to simulate porous cancellous bone in the femoral head 
machined to fit into a custom-made polymer shell for mechanical testing. Height (H) = 
50mm, length (L) = 50mm, width (W) = 38mm. 
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Figure 2: Schematic illustration of the tested augmentation patterns 
Top: Concentric distribution of 2 ml bone cement at the PFNA blade base, centre and 
tip. 
Bottom: Caudal and cranial placement of a 2 ml cement cloud and a 1 ml cranial 
cloud. 
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Group Specimens Cement 
volume 
Cement location 
axial 
Cement location 
transverse 
1 Foam 2 ml implant base concentric 
2 Foam 2 ml implant center concentric 
3 Foam 2 ml implant tip concentric 
4 Foam 2 ml implant tip caudal 
5 Foam 2 ml implant tip cranial 
6 Foam 1 ml implant tip cranial 
7 Foam* 3 ml implant tip concentric 
8 Foam* -- -- -- 
9 Human bone "weak" -- -- -- 
10 Human bone 
"strong" 
-- -- -- 
 
 
Table 1: Study-groups 
Groups 1-8 consist of polyurethane foam samples for testing of different amounts 
and localisations of bone cement. Group 8 represents a non-augmented control. * 
indicates groups from a different study13. Groups 9 and 10: human cadaveric 
references. Group-size n = 6. 
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3.2. Instrumentation 
The foam specimens were placed in a custom-made polymer shell to mimic the 
cortex of the femoral head for subsequent load introduction. A special jig was used to 
introduce a 3.5-mm guide-wire in the center of the foam. Perforated PFNA-blades 
(length 100 mm, Synthes GmbH, Bettlach, Switzerland, Figure 3a) were inserted 
over the guide-wire without predrilling to a depth of 38 mm, resulting in a 12 mm 
distance between the implant tip and the apex of the foam. According to the definition 
of Baumgartner et al.18, this led to a suboptimal tip-apex distance of 24 mm to 
provoke failure as seen in clinics. 
 
 
 
 
Figure 3: Instrumentation of foam specimens 
3a: Perforated PFNA blade (Synthes GmbH) 
3b: Side-opening cannula to inject bone-cement through the perforated blades 
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Subsequently, cement augmentation was performed through the cannulation of the 
blades for each study group following a standardized technique. In all augmented 
groups, the guide-wire was removed and a side opening cannula (Vertebroplasty 
Needle Kit, 8 Ga, Article number: 03.702.216S, Synthes GmbH, Oberdorf, 
Switzerland) (Figure 3b) was prefilled with PMMA bone-cement (Vertecem V+, 
Synthes GmbH, Oberdorf, Switzerland). Thereafter, 2 ml (groups 1-5) or 1 ml (group 
6) of PMMA was injected through the perforations of the blade into the foam 
specimens by using 1 ml syringes (Traumacem V+ Syringe Kit, Article number: 
03.702.130S, Synthes GmbH, Oberdorf, Switzerland). In groups 1-3, 2 ml of PMMA 
was concentrically distributed around the blade's base (group 1), center (group 2) or 
tip (group 3) by injecting 1 ml of PMMA to the cranial side, turning the cannula by 
180° and injecting another 1 ml of PMMA to the caudal side. 
The cannula was either completely inserted (group 3) and subsequently withdrawn 
by 7 mm (group 2) or by 12 mm (group 1) to position the cement at the respective 
localisation along the blade axis. In group 4, a total of 2 ml PMMA was placed at the 
caudal side of the blade by inserting the cannula completely, injecting 1 ml of PMMA 
to the caudal side, withdrawing the cannula by 7 mm without turning it and injecting 
another 1 ml to the caudal side. In group 5, a total of 2 ml of PMMA was placed at the 
cranial side of the blade by inserting the cannula completely, injecting 1 ml of PMMA 
to the cranial side, withdrawing the cannula by 7 mm without turning it and injecting 
another 1 ml to the cranial side. In group 6, 1 ml of PMMA was injected to the cranial 
side of the blade after inserting the cannula completely into the cannulation of the 
blade (Figure 2). 
By prefilling the cannula with cement and by inserting it deep enough to enable the 
side opening to directly reach the perforations of the blade in all study groups, the 
exact amount of PMMA injected into the bone model was known. Because the 
polyurethane foam model allows for a well-controlled cement distribution13, a 
consistent cement configuration could be obtained for each of the study groups 
(Figure 4). 
Human specimens were instrumented according to a recently published protocol14 
according to the procedure described above without augmentation and without using 
the polymer shell. 
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Figure 4: Overview of cement configurations for each of the study groups 
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3.3. Mechanical testing 
The testing model, initially described by Sommers et al.19 and further adapted in our 
recent studies,13,14 simulating an unstable intertrochanteric fracture, was also used in 
this experiment. The setup allows the head component to rotate into varus, while the 
blade migrates through the foam structure. The polyurethane foam samples were 
placed in a plastic shell for load introduction. 
Testing was performed on a servo-hydraulic testing machine (model 858, Mini Bionix; 
MTS, Eden Prairie, USA) equipped with a 25 kN load cell. The force progression in 
the human hip during normal gait as provided by Bergmann et al.20 was cyclically 
transferred to the specimen in physiological orientation of the load vector13, 
simulating an alternating load during walking. In order to achieve a 16° resultant load 
vector to the vertical, a 130° femoral neck angle, and a 3° offset of the femoral shaft 
axis from the sagittal plane, the implant shaft was mounted to a base fixture at 149° 
to the horizontal free to slide along its axis (Figure 5). A cross-table was used to 
eliminate parasitic forces during testing. Starting at 1000 N the load was 
monotonically increased by 0.1 N/cycle until failure of the construct according to the 
protocol of Windolf et al.21 The load-valley was maintained at 100 N throughout the 
test. Cyclic testing was performed at 2 Hz. 
Testing was stopped when the crosshead displacement exceeded 8 mm. Failure 
occurred at the implant to bone or cement to bone interface depending on the 
localisation of the PMMA and was determined by analysis of the X-Rays that were 
performed throughout the test (for details on X-Ray monitoring: see "Data acquisition 
and evaluation" section). 
Human specimens were cyclically tested in a similar manner according to a recently 
published protocol.14 Load was not introduced via the polymer shell but directly 
transferred to the head using a moulded cup. 
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Figure 5: Test setup 
Foam specimen on testing machine. Loading is cyclically introduced to the polymer 
shell under physiologic orientation. Varus rotation of the sample is monitored by 
periodic X-rays. A K-wire attached to the shell acts as marker for X-rays evaluation. 
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3.4. Data acquisition and evaluation 
A K-wire was connected to the polymer shell / human femoral head in the 
mediolateral plane to monitor progression of varus rotation of the specimens from 
radiologic images during testing. A C-arm (Arcadis Varic, Siemens Medical Solutions 
AG, Munich, Germany) was positioned in anteroposterior direction. Radiographs 
were taken every 250 cycles at minimum load (100 N) to monitor the plastic varus 
deformation of the test specimens in relation to the blade. The change in angulation 
of the K-wire with respect to the initial X-ray was determined from the radiographs by 
means of image processing algorithms (Matlab, Mathworks Inc., Natick, USA). 
Retrospectively, a varus collapse of 2° was defined as the point of failure.13,14 This 
failure criterion is a pure varus rotation as all other movements (translation, torsion 
around the blade axis) were eliminated by the design of the test fixture and cannot 
occur. Implant bending was not observed in any of the tested specimen. The number 
of test-cycles to failure was identified for all specimens. 
The radiographs were further analyzed to identify the distance of the center of the 
PMMA volume to the apex of the foam sample for group 1 (blade base), group 2 
(blade center) and group 3 (blade tip). The centroid of the projected cement volume 
was estimated by fitting an ellipse to the cement contour. The six human specimens 
having survived most cycles until 2° varus collapse occurred formed the "strong" 
cadaveric reference group, whereas the remaining six specimens were allocated to 
the "weak" cadaveric group. 
 
3.5. Statistics 
Shapiro-Wilk tests served as decision criterion for the appropriate test statistics. All 
study-groups were compared with respect to number of cycles to 2° varus rotation 
employing a univariate ANOVA (analysis of variance) with Bonferroni post-hoc 
correction for multiple comparisons. Additionally, Pearson’s correlation coefficient R 
was calculated for cycles to failure and localisation of the PMMA volume along the 
implant axis by pooling study-groups 1, 2 and 3. BMD of the "weak" and "strong" 
cadaveric specimens were compared using a t-test. The significance level was set to 
α = 0.05. 
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4. Results 
The performances of all study groups are illustrated in Figure 6. The number of 
cycles to failure for each study group is mentioned in the according bar as follows: 
mean ± standard deviation. Regardless the augmentation pattern, all augmented 
foam samples survived significantly longer than the non-augmented foam group 
(group 8, all p < 0.001). However, there was a clear influence of the augmentation 
pattern on the mechanical competence of the construct. The best performance was 
seen in the 3 ml group (group 7) with 253% increase in cycles to failure compared to 
the non-augmented control. 
However, the performance of this group was not significantly different to 2 ml cranial 
cement placement at the implant tip (group 5, p > 0.99). The least competent 
augmentation pattern was 2 ml cement at the implant base (group 1) leading to 99% 
increase in cycles to failure compared to the non-augmented control. However, there 
were no statistical differences between the latter group and 2 ml caudal placement at 
the implant tip (group 4, p > 0.99) or 1 ml cranial placement at the tip (group 6, p > 
0.99). 2 ml cranial cement placement (group 5) was significantly superior to 2 ml 
cement at the caudal side (group 4, p < 0.001). 2 ml cranial cement (group 5) was 
also superior to 1 ml cranial cement (group 6, p = 0.001). 
The distance of the centre of the PMMA volume to the apex of the foam correlated 
inversely with the number of cycles to failure (R = 0.77, p < 0.001). 
Bone mineral density of the "weak" and "strong" cadaveric groups (groups 9 and 10) 
was 143 ± 35 mgHA/cm3 and 195 ± 33 mgHA/cm3 (mean ± SD), respectively. This 
difference was significant (p = 0.023). Cycles to failure of the "weak" cadaveric group 
(group 9) were not statistically different to the non-augmented foam group (group 8, p 
> 0.99). Cycles to failure of the "strong" cadaveric group (group 10) were not 
significantly different to the augmented foam groups (all p > 0.99). Exceptions were 2 
ml cranial cement placement at the tip (group 5) and 3 ml cement at the tip (group 7), 
which both performed superior to the “strong” cadaveric group (both p < 0.009). 
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Figure 6: Performance of study groups 
The number of cycles to failure for each study group is mentioned in the according 
bar as follows: mean ± standard deviation. 
6a: Number of cycles to failure of the 6 foam groups (groups 1 to 6). 
6b: Number of cycles to failure of an augmented foam group with concentric 
distribution of 3 ml of PMMA at the blade tip (group 7) compared to a non-augmented 
foam-group (group 8) obtained from re-evaluation of the mechanical test raw data of 
a former study. 13  
6c: Human cadaveric reference groups (groups 9/10) obtained from the testing of 6 
human cadaveric femoral heads that were instrumented with a helical blade without 
augmentation for the present study and the re-evaluation of the mechanical test raw 
data of the 6 non-augmented cadaveric femoral heads of a former study.14  
Bars represent mean ± standard deviation of 6 specimens. 
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5. Discussion 
The technique of cement augmentation of PFNA blades for enhanced fracture 
fixation in porous bone already showed promising results in several biomechanical 
studies. A first study, performed on foam models mimicking osteoporotic bones, 
showed a beneficial effect of augmentation on implant stability by an increased cut-
out resistance.13 Two other studies, performed on osteoporotic cadaveric bones, 
showed an increased rotational stability, pull-out resistance and cut-out resistance of 
augmented bones compared to a non-augmented control group.12,14 
A first clinical study on the use of PFNA augmentation also shows promising 
radiological and functional results without major intra-operative complications.15 
Nowadays, augmentation of the femoral head through a cannulated and perforated 
PFNA blade is gaining acceptance amongst surgeons. By using a side-opening 
cannula for cement application it is aimed to selectively position the cement at the tip 
of the helical blade. The risk of cement leakage into the fracture site16, 23-26 or at the 
level of the sliding mechanism of the nail is thereby reduced. Cement leakage into 
the hip joint through a perforation of the femoral head, frequently created during 
guide-wire placement, can be excluded by performing a leakage test prior to 
augmentation.15 However, clinical and experimental experience shows that controlled 
positioning of the cement volume inside the bone is not always possible.14,15 Cement 
follows the path of least resistance and cannot always be sufficiently directed by the 
injection procedure. The question arises to which extent an unfavourable cement 
localisation can compromise the desired biomechanical benefits. Moreover it is 
unclear to which extent the amount of cement can be reduced to exclude potential 
complications such as leakage or thermal necrosis.16, 23, 26, 28 
This in vitro study compared selected cement amounts and patterns along and 
transverse to the PFNA blade axis in a foam model. An overview of the various 
cement configurations is shown in figure 4. It is clear that the cement distributions in 
foam are not fully comparable to the distributions in human bone. The questions how 
and why certain cement distributions in human bone occur, belong to a separate 
topic and are beyond the scope of this study. Foam was used in our experiments for 
sake of reproducibility of cement patterns.  This allowed us to investigate the 
mechanical consequences of specific cement localizations. A clear effect on implant 
purchase of both, localization and amount of PMMA became obvious. The 
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biomechanical competence of the construct increases with placing the cement 
towards the tip of the implant. This finding can be explained by the lever-arm 
principle. A longer lever to the hip joint contact force generates higher moments 
acting on the anchoring point of the implant. Reducing the lever creates a 
biomechanically superior situation. In a clinical context this basic principle was 
already stated by Baumgartner et al.18 stressing the importance of the tip-apex 
distance for hip fracture fixation. On the other hand, care should be taken from a 
biological point of view not to inject the PMMA too close to the subchondral area to 
avoid potential cartilage damage.29 Concerning the influence of PMMA localisation 
transverse to the blade axis, this study showed that a caudal localisation of PMMA in 
relation to the blade is biomechanically inferior compared to cranial or concentric 
position. 
This appears intuitive since physiological loading is dominated by compression and 
PMMA based bone cements provide superior performance under compression than 
tension. From a handling perspective it might be easier to create a concentric cement 
volume. From a biomechanical point of view, however, cement placed cranial to the 
implant tip seems most promising. 
When considering the amount of PMMA in addition to the localisation, this study 
showed that a cranial localisation of 2 ml of PMMA is comparable to a concentric 
localisation of 3 ml around the blade tip. Furthermore, a 1 ml cranial cement 
placement revealed comparable resistance against cut-out as a 2 ml caudal cement 
position. Provided that reliable augmentation of biomechanical superior bone regions 
becomes possible, the volume of cement could hypothetically be reduced to 1 ml. 
For clinical interpretation of our findings a comparison with data from non-
osteoporotic human bone was necessary. In general, the aim of augmentation is to 
rule out the influence of osteoporosis by enhancing the purchase of implants to a 
level similar to healthy bone. From a group of 12 cadaveric samples the six best 
performing specimens were selected to form a "healthy" reference group. Rather 
than clustering the cadaveric samples according to BMD, grouping into "weak" and 
"strong" was performed according to cycles to failure because the target parameter 
of the study was mechanical bone strength and not mineral density. 
When comparing the average BMD of the "strong" or "healthy" group (~200  
mgHA/cm3) to the literature (BMD range approx. 90-290 mgHA/cm3, 174 specimens) 
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this appears to be a reasonable assumption.30 All augmented study-groups 
performed as well or better than the non-augmented cadaveric benchmark, 
suggesting that even unfavourable augmentation patterns can provide a sufficient 
biomechanical benefit. This implicates that clinical difficulties with cement positioning 
might be of minor importance. From another perspective, the use of 3 ml of bone 
cement at the tip of the PFNA blade could even be considered too much. 
It has to be emphasised that these are all theoretical considerations and there are 
some limitations associated with the study. Polyurethane foam can only resemble 
human cancellous bone in a restricted way. However, the approach is still powerful, 
since the homogeneity of a synthetic material offers reproducibility of tests which is 
impossible to achieve with biological bone samples. The foam material was 
successfully used in a previous study13 and compared to a group of human bone 
samples with low bone mass (average BMD 143 mgHA/cm3). No statistical difference 
was found between non-augmented foam and human bone under cyclic loading, 
supporting the similarity between the synthetic material and human bone. In the 
actual study, a group of 12 cadaveric human femoral heads was used to create a 
benchmark of 6 “healthy” bones. On a mechanical base, the 6 weaker specimens 
were discarded to come closer to a “healthy benchmark” than when using all 12. 
Especially when taking into consideration the mean age of the donors (87.2 years), it 
is quite likely that not all were in healthy shape. However, defining the exact value of 
benchmarks of human cadaveric bones requires a separate study what is beyond the 
scope of this work. 
Furthermore, care should be taken when applying the results of our study to the 
clinical situation. It remains difficult to control the localisation of PMMA around 
implants in human bones. Thus, radiographic monitoring of the cement distribution 
during augmentation is crucial. Subchondral localisation or leakage must be avoided 
and the procedure should be stopped as soon as cement flows into undesired 
directions. New methods or instruments for controlling/predicting the cement flow 
during injection are needed to increase the procedural security. PMMA formulations 
have evolved in terms of viscosity and curing window, but they can be further 
optimized. These findings stress the promising and challenging aspects of implant 
augmentation in osteoporotic bone. 
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6. Conclusion 
In this study, we could show that the mechanical competences of all groups of 
augmented specimens are comparable to the mechanical competences of non-
osteoporotic cadaveric bones, independently of the augmentation pattern or the 
amount of PMMA used. Given the fact that in clinical practice control of PMMA 
distribution is not always possible, this finding implicates that even in an unfavourable 
localisation from a biomechanical point of view, augmentation is still better than no 
augmentation. Nevertheless when the cement immediately flows to a superior 
position from a biomechanical point of view, the amount of injected PMMA can even 
be further reduced. On the other hand, an augmentation procedure can be halted 
after injection of 2 ml of PMMA in an undesired direction, making multiple attempts to 
direct more PMMA to other localisations avoidable.  In both situations, the amount of 
injected PMMA can be reduced to an absolute minimum what will decrease the risk 
of cement leakage or cartilage damage. 
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1. Hip fracture prevention  
Of all fragility fractures, hip fractures constitute the most dramatic complication of 
osteoporosis. This can be explained by their associated high morbidity, mortality and 
the health care related costs they induce.1-5 Furthermore, osteoporotic hip fracture 
patients are at the highest risk to sustain a secondary osteoporotic fracture.6 Besides 
an important evolution in the surgical techniques to treat hip fractures during the last 
decades7-10, the care for fragility hip fracture patients has significantly improved with 
the introduction of clinical pathways and co-managed or orthogeriatric care.11-14 
Despite their positive impact, these interventions mostly focus on in-hospital and 
short-term results.15 Because patients with fragility hip fractures are highly 
susceptible for recurrent fractures, the possible role of the surgeon treating the first 
fracture should be considered in preventing subsequent fractures. In a first part of 
this doctoral thesis project, the problem of secondary fracture prevention in the 
context of a geriatric-traumatologic fracture prevention program was explored. 
 
Chapter I: The impact of care pathways for fragility hip fracture treatment on 
  one year mortality: systematic literature review and meta-analysis. 
In this first chapter, a systematic review of the available literature on the subject was 
performed. As primary research question, the effect of care pathways for fragility hip 
fracture treatment on the six months and one-year mortality has been checked. 
Secondary research questions were the prescription of anti-osteoporosis medication 
and the effect of care pathways on recurrence fracture rate. Four randomized 
controlled trials16-19 and seven non-randomized studies20-26 have been included in a 
meta-analysis. This meta-analysis could only prove a significant effect of care 
pathways on one-year mortality for the non-randomized controlled studies. 
Furthermore, none of the included studies reported recurrent fracture rate and data 
on antiresorptive therapy were scarce. 
With the performance of this meta-analysis, a more uniform evaluation of the existing 
clinical pathways for fragility hip fracture treatment was realised compared to 
previously performed studies where different types of orthogeriatric fracture care 
were included. Due to the rigorous inclusion criteria, only evidence based 
approaches based on multidisciplinary and integrated care, were withheld. However 
it was not easy to come to conclusions.  
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Only a small number of studies could be included reporting on the long-term 
mortality. Because there were only four randomized controlled trials, it was decided 
to perform a separate analysis for the seven non-randomized studies that were 
withheld. We realize that the inclusion of non-randomized trials enlarges the risk of 
bias and therefore, a critical evaluation of the non-randomized studies was 
performed. Concerning the influence of clinical pathways on the occurrence of 
recurrent fragility fractures, only poor information about the administration of anti-
osteoporosis medication was found and no data about the occurrence and number of 
recurrent fractures could be retrieved.  Most of the programs focused on peri-
operative interventions and were aimed at short-term results. 
So this review of the literature and meta-analysis confronts us to some gaps in our 
current knowledge. Primarily, there is almost no information available in the actual 
literature on the inclusion of fracture prevention measures in clinical pathways for 
fragility hip fracture treatment. Secondly, only a few studies report on the possible 
role of the surgeon treating the first fragility hip fracture in secondary osteoporosis 
prevention.27,28 Thirdly, there is an urgent need to document the long-term results  of 
the existing clinical pathways on fragility hip fracture treatment. 
 
Chapter II: The impact of a traumatologic-geriatric post-fracture program for 
  osteoporotic hip fracture patients. 
To answer the questions raised after the performance of the meta-analysis of chapter 
1, a clinical pathway aimed at the prevention of recurrent fragility fractures was 
developed, implemented on the traumatology ward and evaluated. 
The development of the pathway was performed by a close collaboration between 
the Traumatology Department and Center for Metabolic Bone Diseases. All patients 
above the age of 65 who sustained a fragility hip fracture and who were able to come 
to the center for metabolic bone diseases on an ambulatory base, were included.  
The following key interventions were performed: 
1. The administration of calcium (1000 mg) and vitamin D (800 IU). 
2. The systematic referral to the Center for Metabolic Bone Diseases for the 
evaluation and treatment of the underlying osteoporosis. 
3. The providing of information about the clinical pathway to the patient, her / his 
family and general practitioner. 
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To evaluate the pathway, a retrospective study was performed by patient chart 
analysis. Two study groups were created: an intervention group of patients subjected 
to the program and a historical control group treated by standard care. Demographic, 
process and outcome parameters for both groups were compared. 
A significant difference was observed between the two study groups for all process 
parameters. However the traumatologic-geriatric post-fracture program did not lead 
to a significant reduction in the number of recurrent fractures or to a mortality 
reduction within the first year after the fracture. 
With this project, two important innovations were achieved. At first, surgeons treating 
fragility hip fractures, were actively involved in secondary fracture prevention. With 
the implementation of the pathway, information sessions were organized for all co-
workers of the traumatology department and refresher sessions are being organized 
on a yearly base to highlight the main points of the pathway. We introduced a 
sensibilisation for the problem of the underlying osteoporosis: patients with other 
fragility fractures than hip fractures were informed as well about osteoporosis by our 
co-workers (medical and paramedical) and an appointment to come to the center for 
metabolic bone diseases often was provided. 
Secondly, in the comparative study, the intended long-term follow-up of one year 
could be achieved. 
The results showed a significant impact of the care pathway on all process 
parameters (with all p < 0.001). This expressed a profound sensibilisation for the 
problem in all co-workers involved. The same sensibilisation was found within our 
geriatric patient population, expressed by the relatively high compliance to referral 
(70.95%). However, a significant impact of the pathway on the number of recurrent 
fractures and the mortality in the year following the fracture, could not be shown. This 
is probably due to the relative short follow-up time despite the intended period of one 
year. When looking at the study results in detail, the mean time for referral to the 
center for metabolic bone diseases was 77 days or 2.5 months. With a mean follow-
up time of 10 months (a one-year follow-up time was achieved for 78.24% of the 
included patients), the real follow-up time starting from the administration of 
antiresorptive therapy was only 7.5 months. In the large-scale studies on 
antiresorptive therapy29,30, the relative risk reduction of recurrent hip fractures started 
at 12 months and progressively increased until the end of follow-up at 36 months.  
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So the non-significant trend in lower numbers of recurrent fractures we observed in 
our study, might represent the start of a similar evolution. 
 
A first perspective for future research consequently will be to extend the follow-up 
time of our study. Another perspective will be to include fall evaluations and fall 
preventive measures in a more standardized way, as falls prevention is an essential 
component of any strategy aimed at reducing fracture risk in the elderly.31 A last 
perspective will be to introduce a general traumatologic-geriatric co-managed care 
pathway for hip fracture patients. The added value of this program will be to provide 
structured and integrated care to this frail patient population of elderly hip fracture 
patients. 
 
2. Hip fracture fixation 
Besides the previously described evolution towards co-managed care for fragility hip 
fracture patients, there has been a simultaneous evolution in implant designs. 
Although there is no evidence yet that the use of intramedullary implants for the 
treatment of intertrochanteric hip fractures lead to better outcomes compared to plate 
and screw systems, there is a trend towards the use of nails and further research on 
new designs of intramedullary nails aiming at a reduction of peroperative fractures 
has been encouraged.9,32,33 Furthermore, there is an evolution towards the use of 
helically shaped implants instead of screws to fix the proximal fracture fragment.34,35 
Despite the biomechanical advantages of these implants, failures do still occur. Cut-
out is one of the most devastating complications and consists of a perforation of the 
cephalic implant through the femoral head followed by a secondary varisation of the 
femoral head. Besides surgeon related causes like incomplete fracture reduction and 
suboptimal implant positioning36-38, it was found that cut-out is strongly related to the 
bone quality of the femoral head.39,40  
In a second part of this doctoral research project, a number of biomechanical 
investigations have been performed aiming at a better implant fixation in osteoporotic 
femoral heads. Therefore, the principle of implant augmentation was explored. This 
principle is based on increasing the implant to bone interface by the addition of bone 
cement, reducing the stresses on the trabecular structures.  
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In the past, large amounts of bone cement have been used to fill pre-drilled voids or 
fracture gaps. Due to the associated complications like delayed or non-unions, 
thermal necrosis and blocking of the sliding mechanism of the implants, a new 
technique of augmentation through the implant has been developed and tested in 
three biomechanical studies. 
  
Chapter III: Biomechanical evaluation of bone-cement augmented proximal 
  femoral nail antirotation blades in a polyurethane foam model with 
  low density. 
In this study, a polyurethane foam model mimicking osteoporotic bone was used to 
test cement augmentation of the perforated helical blade of the proximal femoral nail 
antirotation.41 Four study groups were created comprising non-augmented and 
augmented helical blades in a centered and off-centric position. This change in 
position enabled us to investigate the influence of a biomechanically inferior position 
of the implant, like it sometimes is noticed in practice.  Augmentation was performed 
with the injection of 3 ml of polymethylmethacrylate (PMMA) through the cannulation 
and the perforations of the helical blade. By turning the cannula 360° during the 
PMMA-injection, a circumferential cement distribution around the implant tip was 
obtained. Subsequently, biomechanical testing of all specimens was performed by 
the use of a model mimicking an unstable intertrochanteric fracture.42 The test results 
clearly showed a better performance of the augmented implants. Secondly, from a 
biomechanical point of view, augmentation even had a bigger influence in suboptimal 
implant positions. 
The innovative aspects of this study are the possibility to perform the augmentation 
procedure through the implant without the need to create a void. In this way, it is not 
possible to miss the correct place for implant insertion. Furthermore, no PMMA 
leakage can occur at the fracture site because the cement is distributed around the 
tip of the implant. Finally, there is an important reduction of the risk for avascular 
necrosis of the femoral head because of the small amounts of PMMA (maximum 3 
ml) used as there has been shown a correlation between the amount of PMMA used 
and the heat production in the bone surrounding the PMMA.43 
Nevertheless, a lot of concerns rose when extrapolating these testing results to 
clinical practice.  
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At first, a perforation of the femoral head by drilling the K-wire could lead to cement 
leakage into the hip joint. Secondly, until now, we do not have an instrument at our 
disposition to measure the quality of the bone peroperatively. This means that the 
decision to augment or not, completely depends on the findings of the surgeon 
performing the procedure. Thirdly, there are some concerns about implant removal. 
Can the extraction of an augmented implant cause problems in practice: will the 
cement shear off the implant and will it be possible to drill through PMMA remnants? 
Finally, implant augmentation is used to enhance the implant to bone interface 
reducing thereby the risk of implant failure due to osteoporosis. The even better 
results of augmentation of implants in biomechanically less favourable positions, 
could encourage surgeons to accept mal-positioning of implants and to use 
augmentation as a solution for bad surgery what was not intended at all. 
 
Chapter IV: Potential of PMMA cement-augmented helical PFNA blades to 
  improve implant stability - a biomechanical investigation in human 
  cadaveric femoral heads. 
In this study, an equal biomechanical testing as in the study on foam models was 
performed on study groups of non-augmented and augmented helical blades 
implanted in cadaveric femoral heads.44 Before implantation of the helical blades, 
bone mineral density was measured by peripheral quantitative computed tomography 
(pQCT) and only cadaveric bones with a bone mineral density representative for the 
overall elderly population, were included. When performing the augmentation 
procedure in cadaveric bones, it was noticed that a more heterogeneous cement 
distribution around the implant was achieved despite the fact that the same 
standardized technique of circumferential PMMA injection was used in all test 
specimens. Nevertheless, the study results showed that the augmented specimens 
performed biomechanically better than the non augmented ones. Furthermore, it was 
clear that the effect of augmentation was reduced with increasing bone quality, 
suggesting that PMMA augmentation is primarily useful in the most osteoporotic 
bones. 
This biomechanical study on a cadaver model brought the technique of implant 
augmentation closer to clinical practice.  
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Following the technical problems occurring when performing the augmentation 
procedure of helical blades in cadaveric bones, the following adaptations where 
made to the instruments: stronger syringes and a calibrated plunger were provided to 
allow the surgeon to inject the PMMA by hand pressure. 
After publication of the biomechanical testing results, only half of the amount of 
PMMA was provided in the package to perform the procedure as an amount of 3 ml 
of bone cement increases the anchoring capacity of the implants significantly and the 
risks associated to the use of excessive amounts of PMMA can be prevented. 
Furthermore, a market preference evaluation called "Market preference evaluation 
augmented PFNA" was performed to evaluate the technical performance and the 
early clinical results of this new technique. The University Hospitals Gasthuisberg 
participated in this study with study number S52004 with the inclusion of one patient. 
This allowed us to bring the technique of implant augmentation to clinical practice.  
Prior to augmentation, a leakage test was performed to exclude perforations of the  
femoral head to prevent intra-articular leakage of the PMMA. The results of this first 
clinical study about PFNA augmentation proved the feasibility of a standardised 
augmentation technique.45 Blade migration was prevented and good functional 
results were achieved. No major complications were encountered and it was feasible 
to remove the augmented implant if necessary as was shown by some cases. 
Thereafter, a randomized controlled trial was performed called "Proximal Femoral 
Nail Antirotation (PFNA) versus PFNA augmentation: comparison of PFNA versus 
PFNA augmentation for the treatment of closed unstable trochanteric fractures - a 
randomized controlled trial". The University Hospitals Leuven participated in this trial 
as well with study number S54141 with the inclusion of 28 patients. It was the 
primary purpose of this study to evaluate if PFNA augmentation leads to a better 
stability by facilitating early mobilization and full weight-bearing with less pain. As an 
addendum to the clinical study, an intra-operatively bone density measurement was 
added. This measurement was performed by a torque measurement tool, called 
DensiProbeTM (ARI, Davos, Switzerland). This is an important step because there is 
an urgent need to clearly state the indications for implant augmentation.  As most of 
the fragility hip fracture patients don't have a DEXA-scan available indicating their 
bone quality at the moment they sustain their fracture, the decision to augment or not 
completely depends on the personal judgement of the surgeon.  
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It would be a big advantage to have the possibility to perform an objective bone 
density measurement during the surgical procedure to avoid unnecessary 
augmentation procedures. So we expect the need to clearly state the indications for 
augmentation to be solved after the validation of the DensiProbeTM measuring 
results. The inclusion and follow-up of the patients in the randomized controlled study 
have been performed and study results are being calculated and will be available 
soon. 
The only concern still remaining is the unpredictable cement distribution in 
osteoporotic bone. Both clinical trials showed a relatively homogeneous cement 
distribution. However it was not possible to guide the cement to a desired direction, 
sometimes giving rise to unfavourable localisations like for instance more to the 
subchondral areas. This finding encouraged us to set up a third biomechanical study 
evaluating this problem. 
 
Chapter V: Cement augmentation of hip implants in osteoporotic bone: how 
  much cement is needed and where should it go? 
In this third biomechanical study on augmentation of the PFNA helical blade, different 
localizations and amounts of PMMA around the implant were tested.46 The same 
foam model and testing technique as in the two previous biomechanical studies were 
used.41,44 
Six study groups of foam specimens simulating osteoporotic bone were created. In 
each group, a different amount and localisation of PMMA in relation to the helical 
blade was injected. This was possible due to the homogeneous character of the foam 
model, allowing for a well-targeted cement distribution. Furthermore, a benchmark of 
six cadaveric femoral heads instrumented with a non-augmented helical blade, was 
created. The bone quality of these cadaveric bones was measured by peripheral 
quantitative computer tomography and evaluated as good or non-osteoporotic. 
The biomechanical testing results clearly showed that both the localisation and the 
amount of PMMA do have an influence on implant purchase. Furthermore, the study 
showed that any configuration and amount of PMMA used, leads to a biomechanical 
stability of the construct comparable to the stability of the non-augmented cadaveric 
benchmark which was set as a reference point.  
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Finally, biomechanically more superior localisations of PMMA could be identified and 
were localised cranial to the blade and at the blade tip. 
These study results again will have an influence on clinical practice. At first, they will 
allow surgeons to further reduce the amount of PMMA used, thereby reducing the 
risks for cement leakage and cartilage damage. Furthermore, the results will allow 
surgeons to stop the augmentation procedure when the PMMA flows to less 
desirable localisations and make multiple attempts to guide it to another direction 
unnecessary.  
 
Implant augmentation of the proximal femur as investigated in the above described 
biomechanical and clinical studies, only is the first application of a surgical technique 
that leads to a lot of opportunities that can be further explored. As an adjunct to the 
clinical studies on implant augmentation of the proximal femur, a cost/benefit 
analysis, balancing the potential to reduce the 3.6% failure rate with the cost and the  
potential risks of the use of PMMA cement, could be performed. 
Furthermore, the technique of implant augmentation in the proximal femur can be 
extrapolated to other bones susceptible for fragility fractures. Biomechanical studies 
have already been performed on implant augmentation in the distal femur and in the 
proximal humerus. In the distal femur, augmentation of the distal screws of a locking 
plate has been performed with 1ml of PMMA per screw before screw insertion. Study 
results showed an increased stability for the osteoporotic bone model; augmentation 
did not influence the stability of the construct in a non-osteoporotic bone model.47,48 
Besides for the distal femur, the principle of injecting cement through a cannulated 
implant has been applied for the proximal humerus as well. In a first biomechanical 
study49, the feasibility of augmentation through the cannulated and perforated screws 
of a proximal humerus locking plate has been evaluated. The study results showed 
an increased anchorage of the augmented implants. In a second biomechanical 
study on implant augmentation of the proximal humerus50, the augmentation was 
limited to the two screws in the region of the lowest bone density thanks to the use of 
DensiProbeTM, an instrument allowing for local bone quality determination by 
mechanical torque. The study results once again showed that implant augmentation 
led to a significant improvement in primary stability and the use of DensiProbeTM 
allowed for a more selective and limited use of PMMA.  
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For the moment, a first clinical study on implant augmentation of the proximal 
humerus (augmentation of the Philos proximal humerus plate) is running. 
Another perspective following the promising results of our biomechanical studies on 
implant augmentation could be to modify the composition of the bone cement to 
make it more similar to normal, healthy bone. Primarily, the PMMA as used so far is 
rather brittle and has elastic properties that are completely different from those of 
normal bone. It would be very challenging to adjust the composition of the cement to 
create one with exactly the same elastic properties as normal bone.  
Furthermore, the possible toxic effects of PMMA and the exothermic reaction when 
hardening, remain concerns that still need to be solved. 
Finally, when starting to think about changing the mechanical and chemical 
properties of the bone cement, the idea to use the principle of augmentation in an 
intact femur as a mechanical prophylaxis to prevent fragility fractures, can be further 
explored. A first biomechanical study has been performed on this subject evaluating  
a V-shaped cement augmentation of the proximal femur.51 In five pairs of proximal 
femora, one specimen of each pair was augmented by a minimal invasive approach. 
A diverging V-shaped cement volume (PMMA) was injected in the superior and 
inferior femoral neck through only one entry point in the lateral cortex with the aim to 
reinforce the areas exposed to the highest stresses during a fall. Clinical relevant 
fractures could be generated by a dynamic fall set-up simulating a sideways fall. The 
test results showed increased energy absorption of the augmented specimens 
carrying the potential to prevent secondary fractures. Compared to previously 
performed studies on this subject, the amount of PMMA used could be limited, 
decreasing the possible side-effects like toxicity and thermal effects and the 
procedure could be performed in a minimally invasive way. The promising results of 
this study encourage further research on the subject, possibly comprising further 
adjustments to cement configuration. 
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3. Conclusion 
It was the aim of this doctoral research project to address the problems of fracture 
fixation and prevention in osteoporotic bone. 
Concerning fracture prevention, the clinical study on the implementation and the 
evaluation of a traumatologic-geriatric post-fracture program preventing recurrent 
fractures, led to an impact on process outcomes correlated with good postoperative 
care for hip fracture patients and a sensibilisation of health care professionals and 
patients to this growing problem. However, larger studies with a longer follow-up are 
needed to evaluate the effect of the program on outcome parameters like long-term 
mortality and recurrent fracture rate. 
Concerning fracture fixation in osteoporotic femoral heads, the augmentation studies 
showed a clear benefit of cement augmentation on implant purchase and are a 
perfect illustration of experimental research being brought to clinical practice, leading 
to an amelioration of the operative outcomes in a frail patient population. This is 
illustrated by figure 1. Due to its favourable results, the principle of implant 
augmentation opens a lot of opportunities for further research. 
 
 
 
 
Figure 1: Interlinking experimental research to clinical practice (AO-Dialogue 2011; 2: 11) 
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During the last decades, a tremendous increase in osteoporosis related hip fractures 
has been noticed. It is expected that this evolution will continue due to the expanding 
life expectancy and due to the active aging of our population. From a clinical 
perspective, the consequences of fragility hip fractures are devastating: they lead to 
a high morbidity and mortality and include a high risk for secondary fractures. From 
an economic perspective, they lead to an associated increase in health care related 
costs. 
These findings point to important gaps in our current knowledge and define major 
research priorities. First of all, there is the clinical requirement to implement 
integrated referral pathways that will improve secondary fracture prevention. While it 
is clear that surgeons play a pivotal role in managing fracture patients, few research 
initiatives attempted to optimize post-fracture osteoporosis management by a 
surgeon-driven team. Secondly, there is an urgent need for interventional research to 
develop strategies that enhance fixation stability in the osteoporotic proximal femur. 
Despite an evolution in the surgical techniques to treat fragility hip fractures, failures 
of fixation do still occur. Cut-out is one of the most devastating complications and 
consists of a perforation of the cephalic implant through the femoral head followed by 
a secondary varisation of the femoral head. Besides surgeon related causes like 
incomplete fracture reduction and suboptimal implant positioning, it was found that 
cut-out is strongly related to the bone quality of the femoral head. 
The aim of the current doctoral research program was to address both priorities.  In a 
first part (Chapter I and II), the development and the testing of an integrated 
secondary fracture prevention program was addressed. In a second part (Chapter III, 
IV and V), the development and biomechanical testing of a new surgical technique to 
improve implant fixation in the osteoporotic femoral head was addressed. 
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In chapter I, a review of the literature and meta-analysis was performed on the 
impact of care pathways for fragility hip fracture treatment on one-year mortality. 
There was a significant effect of care pathways on one-year mortality for the seven 
included non-randomized controlled studies. None of the included studies reported 
recurrent fracture rate and only poor information about the administration of anti-
osteoporotic medication could be found. Most of the studies focused on peri-
operative interventions and were aimed at short-term results. 
In chapter II, a traumatologic-geriatric fracture prevention program was set up. This 
care pathway was developed in a close collaboration between surgeons and 
geriatricians and included three key interventions. Primarily, calcium and vitamin D 
was administered to all included patients.  Secondly, the patients were referred to the 
Center for Metabolic Bone Diseases (CMBD) for the evaluation and the treatment of 
the underlying osteoporosis. Finally, information about the fracture prevention 
program was provided to the patient, her / his general practitioner and family. 
A retrospective study was performed to evaluate the process and outcome 
parameters. This study showed a clear impact on the process outcomes with a high 
uptake of calcium and vitamin D by the fracture patients, a high compliance with the 
referral to the CMBD and a sensibilisation of all included patients and health care 
professionals involved. Nevertheless, no impact of the program could be shown on 
the long-term mortality nor on the recurrent fracture rate. 
In the remaining chapters, three biomechanical studies on implant augmentation of 
the proximal femur were addressed. The principle of implant augmentation is based 
on an increase of the implant to bone interface by the addition of bone cement.  In 
our studies this was done through the cannulated and perforated helical blades of the 
Proximal Femoral Nail Antirotation. 
In chapter III, a first biomechanical evaluation of bone-cement augmented Proximal 
Femoral Nail Antirotation blades was performed on a polyurethane foam model 
mimicking osteoporotic bone. The test results clearly showed a better performance of 
the augmented implants compared to the non augmented ones. Secondly, 
augmentation even had a bigger influence on constructs with suboptimal implant 
positioning. 
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In chapter IV, the same biomechanical tests were performed on osteoporotic human 
cadaveric femoral heads. In this study, the augmented specimens performed 
biomechanically better than the non-augmented ones as well. Furthermore, the study 
showed that the effect of augmentation was reduced with increasing bone quality, 
suggesting that augmentation is primarily useful in the most osteoporotic bones. 
When performing the augmentation procedures, it became clear that a more 
heterogeneous cement distribution around the implant was achieved in cadaveric 
bones compared to the foam models. 
This last finding was further explored in chapter V.  In this third biomechanical study, 
different localisations and amounts of bone cement around the implant were tested, 
again on a foam model mimicking osteoporotic bone. The testing results clearly 
showed that both the localisation and the amount of cement do have an influence on 
implant purchase. Furthermore, the study showed that any configuration and amount 
of bone-cement used, led to a biomechanical stability of the construct comparable to 
the stability of a non-augmented cadaveric benchmark which was set as a reference 
point. Finally, biomechanically more superior localisations of cement could be 
identified and were localised cranial to the blade and at the blade tip. 
To conclude, both clinical and biomechanical studies could prove their impact on 
osteoporotic hip fracture treatment. Concerning fracture prevention, the clinical study 
on the traumatologic-geriatric post-fracture program led to a sensibilisation of health 
care professionals and patients for this growing problem. However, larger studies 
with a longer follow-up are needed to evaluate the effect of the program on outcome 
parameters like long-term mortality and recurrent fracture rate. 
Concerning fracture fixation in osteoporotic femoral heads, the augmentation studies 
showed a clear benefit of cement augmentation on implant purchase. Due to these 
favourable results, the principle of implant augmentation opens a lot of opportunities 
for further research. In addition, the biomechanical studies are a perfect illustration of 
experimental research being brought to clinical practice, as the first clinical studies on 
implant augmentation of the osteoporotic femoral head are running. The promising 
results of both our clinical and biomechanical studies might ameliorate the outcomes 
of this frail patient population suffering from osteoporotic hip fractures. 
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Ten gevolge van het steeds ouder worden van onze populatie, neemt het aantal 
personen met osteoporose evenals het aantal osteoporose gerelateerde 
heupbreuken toe. Van uit klinisch standpunt zijn de gevolgen van een 
osteoporotische heupbreuk desastreus: dergelijke fracturen kennen een zeer hoge 
morbiditeit en mortaliteit en omvatten een reëel risico op recidieffracturen. Van uit 
economisch standpunt leiden osteoporotische heupfracturen tot een enorme 
toename van de kosten in de gezondheidszorg. 
Deze gegevens duiden op twee belangrijke tekortkomingen in onze huidige kennis 
en onderzoeksprioriteiten. Ten eerste is er de klinische noodzaak om op een 
systematische wijze geriatrische heupfractuurpatiënten te includeren in een 
programma om recidieffracturen te voorkomen. Tot op de dag van vandaag beperken 
chirurgen zich tot het stabiliseren van de botbreuken en hebben zij geen of slechts 
beperkte aandacht voor de behandeling van de onderliggende osteoporose. Ten 
tweede is er de dringende noodzaak om strategieën en technieken te ontwikkelen 
om een betere fixatie van implantaten in de osteoporotische heupkop te verkrijgen. 
Ondanks een reeds doorgemaakte evolutie in de heelkundige technieken om 
osteoporotische heupbreuken te stabiliseren, treden er nog vaak complicaties op in 
de geriatrische patiëntenpopulatie. Het doorbreken van het implantaat doorheen de 
osteoporotische heupkop is een gevreesde verwikkeling dewelke aanleiding geeft tot 
secundaire varisatie van de heupkop. Naast een onvoldoende reductie van de 
fractuur en een suboptimale positie van het implantaat, speelt onderliggende 
osteoporose een belangrijke rol bij het optreden van deze complicatie. 
Het was de doelstelling van dit proefschrift om beide prioriteiten te behandelen. Als 
dusdanig werd de secundaire preventie enerzijds en de fixatie van heupfracturen bij 
de oudere patiënt anderzijds bestudeerd. In een eerste gedeelte van dit proefschrift 
(hoofdstuk I en II) werd de secundaire preventie van heupbreuken behandeld. In een 
tweede gedeelte van het proefschrift (hoofdstuk III tot V) werd een nieuwe 
chirurgische methode bestudeerd om implantaten in een osteoporotische heup te 
fixeren. 
Heupfractuurpatiënten lopen een groot risico om nieuwe osteoporotische breuken op 
te lopen. In het eerste gedeelte van ons onderzoek werd een programma om nieuwe 
breuken te voorkomen, ontwikkeld en geëvalueerd. 
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In hoofdstuk I werd een systematisch literatuurnazicht uitgevoerd over dit 
onderwerp. Dit nazicht toonde aan dat de meeste studies zich enkel richten op korte 
termijn resultaten en dat ze geen informatie verschaffen over het optreden van 
secundaire fracturen noch over maatregelen om nieuwe breuken te voorkomen. In de 
meeste studies werden enkel interventies voorgesteld gedurende de peri-operatieve 
periode en werden enkel korte termijn resultaten nagestreefd. 
In hoofdstuk II werd een programma voorgesteld om nieuwe breuken te voorkomen. 
Dit programma is gebaseerd op de samenwerking van de chirurgen die de 
heupbreuk behandelen en de geriaters, die zich richten tot de oudere patiënten in het 
algemeen. Alle patiënten die in het programma geïncludeerd werden, kregen calcium 
en vitamine D en werden verwezen naar het Centrum voor Metabole Botziekten van 
de UZ Leuven voor een evaluatie en behandeling van de onderliggende 
botontkalking. Daarnaast werden de patiënten zelf, hun familie en hun huisarts op de 
hoogte gebracht van het programma. Deze studie leidde tot een duidelijke 
sensibilisatie van zowel patiënten als gezondheidsmedewerkers voor het probleem 
maar de studie kon de overleving na één jaar noch het optreden van nieuwe breuken 
voorkomen. 
Ten gevolge van de slechte kwaliteit van het bot, is het niet altijd even gemakkelijk 
om osteoporotische heupbreuken chirurgisch te behandelen. In een tweede deel van 
dit proefschrift werd het gebruik van cement voor het beter verankeren van een 
implantaat in ontkalkt bot, geëvalueerd. Dit gebeurde door middel van drie 
biomechanische studies. 
In hoofdstuk III werd de toevoeging van cement aan een schroef om de heupkop 
beter te fixeren, op een kunststof model getest. De studieresultaten toonden duidelijk 
de gunstige effecten aan van de toevoeging van cement op de fixatie van de schroef. 
In hoofdstuk IV werden dezelfde testen uitgevoerd op heupbeenderen afkomstig 
van een overleden menselijk lichaam. Dezelfde gunstige testresultaten werden 
bekomen zoals in de studie op het kunststof model. Bijkomend werd vastgesteld dat 
de toevoeging van cement aan het implantaat het meeste effect had in het bot met 
de slechtste kwaliteit. Tenslotte werd vastgesteld dat de verspreiding van het cement 
in de menselijke heupkop meer heterogeen was. 
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In hoofdstuk V werden verschillende lokalisaties en hoeveelheden cement 
vergeleken in een kunststof model. The studieresultaten toonden aan dat bepaalde 
lokalisaties gunstiger waren dan andere. Daarnaast toonde de studie aan dat het 
aanbrengen van cement op iedere lokalisatie aanleiding gaf tot een even stabiele 
constructie als een gelijkaardige constructie zonder cement in normaal (niet ontkalkt) 
bot. Vanuit biomechanisch standpunt situeerden de beste lokalisaties zich craniaal 
van het implantaat of ter hoogte van de tip van het implantaat. 
Om te besluiten kunnen we stellen dat zowel de klinische als de biomechanische  
studies een gunstig effect aantoonden op de behandeling van osteoporotische 
heupbreuken. Voor wat betreft de preventie van recidief fracturen toonde de klinische 
studie aan dat de systematische aanpak van de onderliggende osteoporose door de 
chirurg, aanleiding gaf tot een sensibilisatie van zowel de patiënten als de 
gezondheidsmedewerkers voor dit groeiend probleem. Voor wat betreft de 
fractuurfixatie in de osteoporotische heupkop, toonden de biomechanische studies 
het gunstige effect van augmentatie op de stabiliteit van de constructie aan. Deze 
veelbelovende resultaten zullen ons toelaten de postoperatieve complicaties en 
kwaliteit van leven bij deze kwetsbare populatie van patiënten met een gebroken 
heup verder te verbeteren. 
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